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Utilizing functional genomics approaches to characterize risk genes in alopecia areata 
 Stephanie O. Erjavec 
 
Understanding the genetic architecture of complex disorders is important for identifying 
disease mechanisms and potential molecular targets for therapeutic interventions. Genetic 
diseases are broadly classified as either Mendelian (monogenic) diseases or complex 
(polygenic) diseases. Common, polygenic disorders result from inheritance of multiple common 
variants with low penetrance. In contrast, monogenic, Mendelian disorders are caused by rare 
variants with high penetrance at a single genetic locus. However, an increasing number of 
studies support a role for rare variants of moderate effect size in complex diseases. As a result, 
genetic approaches previously utilized for discovering rare variants in Mendelian diseases, such 
as next generation sequencing, can now effectively be applied to complex diseases to define 
the contribution of both rare and common variants to the genetic burden of polygenic traits and 
diseases.  
Alopecia Areata (AA) is a complex autoimmune disease characterized by non-scarring 
hair loss that is due to a combination of both environmental and genetic factors. Our previous 
Genome-wide Association Study (GWAS) identified at least 14 genetic regions contributing to 
AA disease susceptibility. Although useful in identifying disease-associated loci and surrounding 
linkage disequilibrium (LD) blocks, GWAS is not sufficiently granular to 1) elucidate causal 
(association-driving) variants; and 2) discover rare risk variants. This level of resolution can only 
be achieved by deep sequencing followed by functional validation of variants. 
The goal of this thesis was to address these challenges in AA using two genetic 
approaches that have not been previously utilized in the context of this disease. In Chapter 2, I 
performed a hypothesis-driven analysis of common variants in a GWAS-associated locus using 
targeted genomic sequencing. In Chapter 3, I utilized whole exome sequencing (WES) in an 
 
 
unbiased approach to assess rare variant contribution in AA disease risk. To conduct these 
analyses simultaneously, we designed a whole exome sequencing (WES) chip that also 
included custom capture of 24 Mb of genomic regions covering the 14 genetic loci previously 
identified using GWAS. I applied these two sequencing approaches in a large AA patient cohort 
and identified potentially causal variants in several genes. To interrogate the consequences of 
these variants, I performed functional analyses to determine the effects of disease-causing 
variants on the target organ of AA attack, the hair follicle (HF). 
In Chapter 2, I report on the use of targeted genomic sequencing to interrogate the 
coding and non-coding regions surrounding a previously implicated GWAS locus. This approach 
provided fine mapping of coding and non-coding common variants in regions that may be 
contributing to disease risk. In this thesis, I focused on the effect of genetic perturbations on the 
end-organ HF, and consequentially prioritized my functional analysis using two criteria: 1) genes 
expressed in the (HF) and; 2) GWAS regions that were not previously implicated in other 
autoimmune diseases. One of the regions that satisfied these criteria harbored the Syntaxin 17 
(STX17) gene, which encodes a SNARE protein involved in autophagy and mitochondrial 
fission. Targeted genomic sequencing of the STX17 region in 849 AA cases identified 35 non-
coding and 0 coding variants in high LD with the GWAS SNP. Thirty-three variants were 
significantly enriched in cases compared to controls, and the remaining two were nominally 
significant. Thirty-two of the significantly associated AA variants were confirmed to be AA skin 
eQTLs that downregulated expression of STX17 in affected scalp skin of AA patients. 
Downstream analyses incorporated in silico and functional cell assays that uncovered a novel 
autophagy-independent role for STX17 in melanocyte biology. I discovered that a reduction of 
STX17 expression was associated with an accumulation of a melanocyte-specific antigen and 
increased immunogenicity, as seen by CD8+ T cell infiltrates in the skin of AA patients with low 
levels of STX17 expression. I used a targeted sequencing approach to successfully identify 
 
 
candidate causal variants driving the GWAS association at the STX17 locus, and propose a 
novel mechanism underlying STX17-dependent melanocyte perturbation and AA disease.   
In the second section of this thesis, we used the WES feature of the chip to assess the 
genetic contribution of rare variation in AA, in a genome-wide and unbiased manner. WES data 
and gene-level burden analyses of 18,653 genes in 849 AA patients was compared to 15,640 
controls to identify rare variants associated with AA. Unexpectedly, this analysis identified one 
gene, encoding a hair-specific keratin, Keratin 82 (KRT82) that harbored significantly more rare 
damaging mutations in AA cases compared to controls (p=2.68E-06). Eleven rare damaging 
mutations were found in 51 AA patients in the heterozygous state (6.01%) compared to 2.58% 
controls. These variants resided in evolutionary conserved amino acid residues, and nine out of 
the eleven mutations were located in established disease-causing domains in keratin proteins. I 
determined that KRT82 expression was absent or largely reduced in AA hair follicles, including 
the bulb region, the site of AA immune attack. Moreover, AA patients with damaging variants 
and reduced KRT82 expression had increased perifollicular CD8+ T cell infiltrates in 
comparison to control HFs with intact KRT82 expression remaining. I proposed that damaging 
mutations in the coding regions of KRT82 resulted in loss of functional protein, thereby 
weakening the protective HF cuticle and predisposing the HF to immune attack. 
 In summary, I used two genetic approaches (targeted genomic sequencing and WES) to 
identify common (Chapter 2) and rare variants (Chapter 3) with novel contributions to the 
complex genetic architecture of AA. I focused my functional studies on genes expressed in the 
target HF, with the goal of defining the role of unidentified, variant-mediated end-organ 
disruption in the predisposition of AA patient HFs to aberrant autoimmune attack.  Up to now, 
most efforts in AA mechanistic studies have focused on the aberrant immune response. The 
work in my thesis uncovered novel roles for perturbations in the HF itself as a participating 
factor in AA disease risk. 
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1.1 Genetic Disease and Patterns of Inheritance  
Mendelian Diseases 
The study of human genetics and disease heritability have provided unparalleled insights into 
pathogenic mechanisms underlying human disease. Inherited disorders are transmitted across 
generations by either Mendelian or non-Mendelian modes of inheritance. Mendelian inheritance 
follows a pattern in which genetic alleles are tightly linked to a phenotypic trait. In this model, 
inheriting a pathogenic allele(s) results in disease in a dominant or recessive mode of 
inheritance. In these disease types, penetrance is high and mutations in a single gene strongly 
influence disease development. In 2020, there were approximately 5,550 documented single-
gene traits and diseases 
catalogued in in publicly 
available OMIM (Online 
Mendelian Inheritance in Man) 
database; annotating causal 
genes in disease such as 
Cystic Fibrosis, Sickle Cell 
Anemia, and Huntington’s 
disease3. These diseases are 
usually rare in the general 
population due to purifying 
selection, which prevents the 
accumulation of deleterious alleles within a population. Consequentially, monogenic diseases 
are primarily a result of deleterious rare variants (population Minor Allele Frequency (MAF) < 
0.5%) with high effect sizes in single genes (Figure 1). These pathogenic Mendelian variants 
Figure 1 | Variant Frequency and Disease Associations. 
Rare variants (MAF<0.5%) with large effect sizes (dark blue 
circle) contribute to monogenic diseases while common variants 
(MAF>5%) with smaller effect sizes (brown circle) effect 
complex disease risk and are primarily identified using GWAS. 
Recent evidence suggests low frequency variants with 
moderate effect sizes (light blue circle) may also contribute to 
complex disease. (Adapted2) 
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(mutations) consist mainly of large genomic rearrangements, copy number variants (CNVs), 
insertions/deletions (indels), or rare single nucleotide variations (SNVs)4.   
Complex Diseases 
Unlike Mendelian diseases, complex disorders are the result of multiple genetic 
contributions, as well as environmental factors. These disorders are more common in the 
general population, and include diseases such as asthma, type I and II diabetes, depression, 
rheumatoid arthritis, and various autoimmune diseases. The central dogma, the ‘common 
disease-common variant’ model, asserts that common, complex diseases are caused by low 
effect, common variations (MAF > 5%) across multiple genes (Figure 1).  Common variants 
often exhibit reduced, or incomplete penetrance, in which the presence of a disease-associated 
allele does not singularly determine whether the individual will develop disease. Rather, other 
factors, such as gene-gene interactions, epigenetic modifications, and environmental effect also 
contribute to disease susceptibility.  In contrast to rare Mendelian mutations with high effect 
sizes, the majority of common disease variants only confer about a 1.1-1.5-fold increase in risk 
(Figure 1) and largely reside in the non-coding regions of the genome2. Due to the low effect 
and heterogenous nature of these variants, it has been more challenging to identify causal 
mutations in complex diseases. Consequentially, the common variants identified up to this point 
contribute to a small proportion of disease heritability, inviting further investigation into factors to 
account for this ‘missing heritability’. This thesis will center around the genomic investigation 
and functional studies of complex disease, Alopecia Areata (AA). To interrogate AA disease 
risk, I utilized two genetic approaches: 1) hypothesis-driven targeted sequencing of a genome-
wide sequencing (GWAS) locus and 2) unbiased whole exome sequencing (WES) (discussed in 




1.2 Role for rare variants in complex diseases  
Several models have been proposed in an attempt to explain the missing heritability of 
polygenic disorders. Some authors speculate that our lack of understanding of the genetic 
architecture of complex diseases can be attributed to environmental factors, gene-gene 
interactions, chromosome structural variants, or the need for increased power of cohorts in 
order to detect larger numbers of small effect variants2. Interestingly, an increasing number of 
studies have reported a role for rare and low frequency variants of moderate effect size in 
complex diseases (Figure 1). Although rare variation (with large effects) was once thought to 
contribute mainly to Mendelian diseases, the contribution of rare (MAF < 0.5%) and low 
frequency (0.5% < MAF < 5%) variants to common disease risk is increasingly emerging. A 
wide variety of complex disorders such as congenital kidney malformation, amyotrophic lateral 
sclerosis (ALS), pulmonary fibrosis, epilepsy, coronary artery disease, myocardial infarction, 
and autism have all found rare variants that significantly associate with disease5-11. The 
identification of novel, low frequency variants with modest effect sizes have thus been shown to 
play a role in the genetic architecture of complex diseases and could feasibly explain a 
significant portion of the ‘missing heritability’. In Chapter 3, we investigated the effect of novel, 
rare variants on risk susceptibility in AA. 
 
1.3 Types of pathogenic variants  
Structural Variants 
Both monogenic and polygenic diseases result from DNA alterations known as 
mutations or variants. Disease-causing variations can affect both the non-coding (intronic, 
intergenic) and coding regions (exonic) of the genome. Chromosomal structural variations 
include insertions, deletions, duplications, translocations, and inversions that span >1 kb of the 
chromosomal DNA (Figure 2)12. Copy-number Variations (CNVs) are a subcategory of structural 
variants that result in genomic imbalances due to large insertions or deletions of chromosome 
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Figure 2 | Effects of genomic variants. Types of structural, 
coding, and non-coding variants and their corresponding 
consequences. Figure generated using BioRender.  
regions12. CNVs span > 1 kb, 
often resulting in the disruption 
of multiple genes, and 
complicating the identification 
of a definitive disease-causing 
gene. 
Coding Single Nucleotide 
Variants 
 Single Nucleotide 
Variants/Polymorphisms 
(SNVs/SNPs) are variants that result in single nucleotide alterations, including both 
insertions/deletions (indels) and substitutions. SNVs that affect the coding, exonic regions of 
genes are classified as either synonymous or non-synonymous. Synonymous, or silent, 
substitutions modify the nucleotide base pair without affecting the resulting amino acid 
sequence (i.e. CGT, CGC, CGA, CGG = arginine) (Figure 2). These are generally considered 
benign, since the protein product remains unchanged.  
Non-synonymous mutations are more likely to be pathogenic due to a change in the DNA 
sequence that results in an alteration of the protein product. Missense mutations are classified 
as nucleotide substitutions that change the corresponding amino acid in the protein sequence 
(Figure 2)13. Nonsense mutations incorrectly introduce a stop codon, resulting in a prematurely 
truncated protein13. Additionally, 1-2 nucleotide indels (or insertions/deletions of any number of 
nucleotides not divisible by 3) typically result in frameshift mutations that alter the mRNA 
reading frame and disrupt all downstream amino acids of the protein (Figure 2)13.  
Non-synonymous mutations can further be classified as loss-of-function (LOF) or gain-of-
function (GOF). Gain-of-function mutations increase gene activity or result in a novel protein 
function. Conversely, loss-of-function mutations, such as nonsense and frameshift mutations, 
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reduce the presence, function, or activity of the gene product. Heterozygotes for loss-of-function 
alleles (carriers) are often asymptomatic due to the ability of the wildtype allele to compensate 
for the reduced function of the mutated allele14. However, haploinsufficiency results when one 
LOF allele causes a reduction of the normal gene product to about 50%, which is not sufficient 
for adequate protein function. In comparison to LOF mutations, predicting the effects of 
missense variants on protein function is not as straightforward. As a result, the PolyPhen tool 
was developed to predict damaging effects of mutations using both sequence and structure-
based predictive models15. PolyPhen assigns coding variants a score of likelihood to be 
damaging and allows prioritization of the predicted damaging mutations for further functional 
analyses. The effect of LOF and damaging coding mutations in AA will be discussed further in 
Chapter 3.  
Splicing Mutations 
Exon-intron boundaries are defined by splice sites that direct the splicing machinery to 
form a mature mRNA transcript consisting of only coding sequences. Most splice sites contain 
5’-GT and 3’-AG motifs at the intron boundaries that are recognized by the splicing machinery to 
bind, cut, remove the intron, and ligate the ends of exons16,17. SNVs occurring in these tightly 
regulated exon/intron junctions can result in improper intron removal and aberrant transcript 
formation (Figure 2). Additionally, splicing mutations can occur at other coding and non-coding 
locations within the gene that result in novel splice sites or splicing regulatory disruption, 
impacting mRNA transcripts and protein translation. In an effort to identify possible causal 
splicing mutations associated with disease risk, in silico algorithms, such as Transcript-inferred 
Pathogenicity (TraP), incorporate predicted splicing effect disruption into their variant 
interpretation tools18. TraP provides pathogenic prediction scores for synonymous and intronic 
SNVs based on gene information acquisition, splice sites/regulatory features, and modeling18. 
As a result, TraP effectively predicts the probability of a synonymous or intronic variant having a 
damaging effect on transcript formation due to interference with the regulatory and/or splicing 
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machinery. In Chapter 3, we incorporate TraP prediction scores to identify potential disease-
causing variants in AA.  
Non-coding Mutations  
Pathogenic variants can also reside in non-coding regions; however, their disease-causing 
effects are not as well characterized (Figure 2 and 3). Non-coding DNA accounts for 98% of the 
human genome and harbors many important gene regulatory elements such as promoters, 
enhancers, and structural elements19. Although not fully understood, non-coding variants can 
exert regulatory effects on downstream gene products through both proximal and long-range 
interactions on surrounding genes. Interestingly, approximately 90% of susceptibility and causal 
variants in autoimmune diseases have been mapped to non-coding regions20,21. The emerging 
realization of the contribution of non-coding regions to disease risk underscores the need for 
further understanding of intronic and intergenic regions. Large consortia such as ENCODE 
(Encyclopedia of DNA Elements Consortium) and Roadmap Epigenomics have propelled the 
field forward through the compilation of datasets annotating the functional landscape of non-
coding regions into publicly available databases22,23. By integrating a wide range of histone 
modifications (acetylation and methylation), DNA binding sites (ChIP-seq), and chromatin 
accessibility (DNase I hypersensitive sites), these databases provide an invaluable resource for 
understanding the non-coding architecture of the genome and identifying the location of 
potential regulatory elements.  
Utilizing these datasets, in silico algorithms, such as RegulomeDB and FUN-LDA 
(Functional-Latent Dirichlet Allocation), were designed to predict the probability of variant 
regulatory effects at individual positions throughout the genome. Our collaborator, Dr. Iuliana 
Ionita-Laza at Columbia University, developed the FUN-LDA algorithm, which integrates histone 
modifications and chromatin accessibility from the ENCODE database to predict the likelihood 
of a regulatory effect at each position of the genome in 127 distinct cell and tissue types24. FUN-
LDA enables functional annotation of any non-coding variant in the genome, and also provides 
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context-dependent regulatory effects based on relevant cell and tissue types. These data help 
to distinguish which cell types are 
relevant to disease and are affected by 
the variant in question. Such large 
regulatory databases and in silico 
models have provided the field with 
invaluable new tools to gain insight into 
the roles of non-coding variants in 
disease pathogenesis.  
eQTL effects of non-coding variants 
One of the most fundamental effects 
of causal non-coding variants is the 
dysregulation of gene expression. Variants 
falling in promoters, enhancers, 
transcription factor binding sites, or DNA 
modification regions all have the potential 
to disrupt transcription and alter gene 
expression levels (Figure 3). In order to identify non-coding variants with direct effects on gene 
expression, eQTL (expression quantitative trait loci) analyses are utilized26. This approach uses 
multi-dimensional patient data to integrate the presence of variant alleles with changes in gene 
expression levels in a targeted tissue type. eQTLs establish a direct correlation between an 
allele and corresponding expression levels in a disease-relevant tissue26. Identification of eQTLs 
allows pinpointing of non-coding variants that have a functional effect on the gene product, and 
thus have a greater likelihood of being causal in disease. Through the use of in silico 
annotations and multidimensional data, our understanding of the role of non-coding variants in 
Figure 3 | Effect of non-coding variants on cell 
type-specific expression. Non-coding variants can 
fall in regulatory regions (enhancer, promoters, etc.) 
that have effects on gene expression in a cell-type 
specific manner. When a variant genotype (GG) 
correlates with altered expression levels of the mRNA, 




complex diseases has made substantial progress. In Chapter 2, we integrate the use of in silico 
algorithms and sequence-expression data to identify potential non-coding causal variants in an 
AA risk locus.  
 
1.4 Genetic approaches for identifying pathogenic variants 
Historically, the genetic approaches used to identify disease-causing variants have been 
dependent on the type of disease inheritance. Rare, Mendelian disorders are primarily mapped 
using family-based linkage analysis, while complex diseases routinely utilize case-control 
genome-wide association studies (GWAS). However, the rapid advancements in next-
generation sequencing (NGS) technology have ushered in new sequence-based approaches to 
identify novel variants in complex diseases. This dissertation focuses on variant identification 
and functional annotation in AA; therefore, we will focus on the genetic approaches available for 
mapping genes in common, complex diseases.  
Genetic Approaches for Mapping Disease Genes 
The two main approaches for gene identification in genetic diseases have been linkage 
analysis in rare diseases and GWAS in common disorders27,28. 
Linkage 
Linkage analysis is based on the principal of co-segregation, in which a genetic region co-
segregates with the disease phenotype in a pedigree of multiple affected individuals. Regions of 
the genome can be inherited together based upon recombination events, in which proximal 
genomic locations are inherited together with higher frequency than distant or intrachromosomal 
locations due to a reduced probability of chromosomal crossover events between the proximal 
loci29. Linkage disequilibrium (LD) occurs when proximal loci are disproportionately inherited 
together across a population, forming haplotypes, or groups of co-occurring alleles on a single 
chromosome29,30. LD is measured by r2 and D’ metrics that take into account the statistical 
comparison of the frequency of an observed haplotype versus its expected frequency in a given 
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population31. r2 and D’ values that approach 1 correlate with increased LD between two genomic 
positions.  
Linkage analysis utilizes the principles of co-segregation and recombination by incorporating 
markers spaced across the genome to identify, in an unbiased manner, chromosomal regions 
that segregate with a disease or trait32. The co-segregating marker tags a genetic allele that is in 
linkage with disease, identifying nearby regions of the genome that may harbor a causal 
disease gene.  The large candidate region can then be further investigated for the causative 
disease gene driving the co-segregation. Gene detection using this method is most effective for 
single genes of complete penetrance32, therefore, linkage analysis has been very successful in 
identifying Mendelian disease genes. Linkage has also been applied with moderate success to 
the genetic mapping of complex disorders, including Type I and II diabetes, Crohn’s Disease, 
Alzheimer’s Disease, psoriasis, atopic dermatitis, and AA in small cohorts of families with 
multiple affected members33-35. Although linkage studies have been moderately successful in 
common diseases, the more fruitful approach is GWAS, a population-based association study 
comparing cases and controls. 
GWAS 
The principles of linkage and LD are also fundamental to understanding population-based 
GWAS association studies30. Association studies employ various markers dispersed across the 
genome to identify regions of association with a trait. The LD architecture of the human genome 
allows association studies to take advantage of marker genotyping without requiring sequencing 
of every genomic base pair36. Since co-occurring alleles in LD blocks are inherited together on a 
haplotype, the markers can successfully identify regions and their surrounding LD blocks that 
are associated with disease status.  GWAS are population-based association studies that 
involve genotyping thousands of individuals at 500,000-2.5million SNPs (tag-SNPs) across the 
genome37. The tag-SNPs involved in GWAS platforms are common (MAF  5%) in the general 
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population due to the basis of the ‘common variant, common disease’ dogma2,36. By genotyping 
individuals with the trait of interest at these pre-determined tag-SNPs and comparing them to 
unaffected controls, we can effectively identify haplotypes that are enriched at increased 
frequency in the trait/disease cohort.  Since these SNPs are common and predicted to be of low 
effect size, large cohorts of patients with a given disease are required in order to identify 
significant associations. GWAS studies have successfully identified >40,000 SNPs significantly 
associated with various complex diseases and traits, conveniently compiled in a publicly-
available database, GWAS Catalogue38.  
Although GWAS is an effective tool for identifying low effect, common disease variants, 
there are two main limitations with this approach. First, GWAS studies utilize SNP arrays that 
contain 500K-2.5M common SNPs, which enable identification of associated regions, but are 
unable to provide the base-pair (bp) level resolution necessary for distinguishing the 
association-driving variant(s) from the non-functional variants on the same haplotype. The tag-
SNP effectively points to a large LD block associated with disease; however, it is not possible to 
determine whether that SNP itself is causal, or whether a proximal variant(s) in high LD with the 
mutation is driving the association. The accurate identification of the causal variant(s) is crucial 
for understanding the effect of the variant, the pathomechanism of disease, and relevant targets 
for potential therapeutics and interventions. As a result, deep sequencing and fine mapping of 
GWAS associated regions used to distinguish the surrounding genetic architecture with higher 
resolution in order to identify the precise causal variant(s) driving disease association at GWAS 
loci.  
The second issue inherent to GWAS relates to the ‘missing heritability’ paradigm of complex 
diseases, in which GWAS findings alone are unable to account for a large portion of genetic 
susceptibility2. Due to the basis of ‘common variant, common disease’ and the use of common 
tag-SNPs on GWAS SNP chips, rare variants are not genotyped. Consequentially, rare disease 
variants are seldom identified using this method36. However, as discussed in section 1.2, there 
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is increasing evidence for the role of rare variants in complex disease risk39-43. Since GWAS is 
an inadequate method for effectively identifying rare variant associations, the recent 
advancements in NGS have enabled the investigation of rare variants in complex disease risk 
(discussed in the next section). In this thesis, we addressed both of these fundamental GWAS 
limitations through (1) targeted sequencing of a GWAS association region to elucidate the 
causal variant(s) driving association in Chapter 2; and (2) investigation of the role of rare 
variants in the genetic architecture of AA using WES in Chapter 3.  
NGS and Complex Diseases 
Due to the high cost and low throughput nature of early sequencing methods, sequencing 
studies were primarily limited to small candidate gene regions identified by linkage analysis in 
large multiplex pedigrees with monogenic diseases44. In the mid-2000s NGS was developed as 
a high throughput sequencing approach that drastically lowered the cost of sequencing45. 
However, at $10,000 USD per genome, NGS approaches were still too costly to sequence large 
sample numbers with the power required to detect associations in complex disease studies44. 
As a result, a more cost-effective method of targeted sequencing in GWAS susceptibility regions 
was developed to follow-up these genetic studies and identify the functional, causal variant(s) in 
the associated regions of interest.  
The development of targeted exon enrichment enabled the emergence of whole exome 
sequencing (WES), which was quickly and successfully applied to monogenic diseases on the 
basis that the majority of monogenic disease variants are rare coding variants with high effect 
sizes46,47. WES was extremely successful in Mendelian diseases and contributed significantly to 
our understanding of Mendelian disease genes. The ability of WES to effectively identify rare 
disease variants made it an attractive approach to address the role of rare variants in the 
missing heritability paradigm of complex diseases48. As NGS and WES technology continued to 
advance, cost continued to decline, and WES became feasible for large-scale studies of 
complex diseases. However, the successful detection of rare variants was dependent once 
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Figure 4 | Gene-collapsing burden analysis. The number 
of qualifying variants that meet study criteria (i.e. MAF<1% 
and damaging effect) in cases (pink) compared to controls 
(blue) in a given gene. (Adapted1) 
again on the need for large sample sizes, due to the lack of power to detect variant level 
associations44,48,49. As a variant’s frequency decreases, the ability to detect significant 
associations also decreases because of the sparse observations of the rare allele in a given 
population1,44. Subsequently, the 
lack of rare allele observations 
inhibits the ability to achieve 
statistically significant associations 
in moderate cohort sizes. To 
overcome the inability to identify 
variant level associations, burden tests were applied to WES data as a method for aggregating 
the variants within a given gene and comparing the frequency of genetic variants in cases and 
controls (Figure 4)44,50. In a gene-collapsing burden test, variants are annotated as “qualifying 
variants” based on specified criteria, such as allele frequency in the general population and 
variant effect50. Variants that meet the parameters are identified as ‘qualifying’ and are then 
combined together based on gene boundaries, thereby determining whether a gene harbors 
more total rare damaging variants in cases compared to controls (Figure 4).  WES and burden 
tests have been successfully applied to many common diseases, including ALS, Alzheimer’s 
disease, myocardial infarction, and schizophrenia6,10,51,52.  In summary, the significant advances 
in NGS technology have allowed adaptation of these methods for complex disease studies in 
both hypothesis-driven (i.e. targeted resequencing of GWAS regions) and unbiased (i.e. WES, 
WGS) approaches.  
I utilized both of these NGS approaches in AA to (1) resolve variant annotations in non-
coding regions of a previously identified AA risk locus (hypothesis-drive approach); and (2) 




1.5 Alopecia Areata 
Clinical Characteristics and Pathology 
Alopecia areata (AA) is one of the most 
prevalent autoimmune diseases, with a lifetime 
risk of 2.1%55. In AA, transient non-scarring hair 
loss is a result of immune-directed attack of the 
hair follicle (HF). The disease can affect any 
hair-bearing site and manifests in three main 
presentations: Alopecia Areata Patchy (AAP), 
Alopecia Areata Totalis (AT), and Alopecia 
Areata Universalis (AU). AAP is the most 
common form of disease and results in well-
demarcated regions of hair loss on the scalp 
(Figure 5). In a subset of cases, disease 
progresses resulting in hair loss of the entire 
scalp (AT) or body (AU). Other rarer forms of 
disease include diffuse alopecia areata, which 
results in widespread hair thinning across the 
entire scalp, and ophiasis, a thick band of hair loss on the occipital scalp hair line. Pathological 
features of AA include yellow and black dots on the scalp, and exclamation mark hairs (EMH). 
EMHs are often found within lesional areas of active disease, and are distinguished as 
fractured, short hairs with frayed distal ends that taper towards the scalp. The presence of 
cuticle defects in these vulnerable/weak hairs may suggest a potential role for disruption of hair 
follicle integrity in AA56.  
AA is a complex genetic disease with an incidence of positive family history reported in 
up to 42% of cases57. Onset can occur at any age, however, an early age of onset (5-10 years 
Figure 5 | Pathology of AA. Patient with AAP 
disease manifestation. Immunohistochemistry stain 
of “swarm of bees” phenotype characterized by 
lymphocytic infiltrate of AA hair follicles. Graphic of 
healthy hair follicle compared to an AA-affected 
hair follicle which upregulates MHC class I and II 
expression and is infiltrated by auto-reactive 
lymphocytes (APCs, NK cells, CD4+ and CD8+ T 
cells). APC= antigen presenting cell, NK cell= 
natural killer cell, MHC= major histocompatibility 




old) tends to correlate with disease severity( i.e. Alopecia Areata Totalis/Universalis (ATAU))58. 
Additionally, AA affects both genders and all ethnic groups equally. Common comorbidities with 
other disorders include atopic dermatitis (39%), autoimmune thyroid disease (8-28%), vitiligo 
(4%), and lupus erythematosus (0.6%)59.  
A positive diagnosis of AA is established by: 1) Clinical evaluation (hair loss pattern; 
AAP, AT, AU); 2) Dermoscopy (yellow/black dots and EMHs); 3) family history and 
comorbidities; and 4) histologic evaluation. The pathognomonic histopathology of AA is 
inflammatory cell infiltrate around the base of the hair follicle (Figure 5). The high density of 
lymphocytic cells in the infiltrate is composed largely of CD8+ T cells that exhibit a “swarm of 
bees” phenotype in affected hair follicles (Figure 5). This inflammatory infiltrate is responsible for 
the hair-follicle directed autoimmune attack and resulting hair loss.  
Another measure of disease diagnosis and progression was developed in our lab using 
molecular gene expression signatures of skin biopsies. The Alopecia Areata Disease severity 
Index (ALADIN) was developed based on gene expression signatures of inflammatory genes 
and correlates with disease severity. AA skin samples have increased cytotoxic T lymphocytes 
(CTL) and interferon (IFN) gene expression signatures and a decreased hair keratin (KRT) 
index that are significantly distinguishable from controls60. The ALADIN metric is dependent on 
expression of the following signatures: CTL (PRF1, CD8A, GZMB, ICOS), IFN (STAT1, MX1, 
CXCL9, CXCL10, CXCL11), and KRT (DSG4, PKP1, KRT31, KRT32, KRT33B, HOXC13, 
KRT82). These groups of genes represent critical molecular signatures that are prominently 
dysregulated in AA skin, providing crucial insight into the underlying pathomechanisms of AA. 
Additionally, the characteristic AA immune signatures (CTL and IFN) support the autoimmune-
driven pathology of hair loss in this disease.  
Autoimmune-directed attack of the hair follicle 
  Autoimmune diseases are a result of modifications in the immune system that result in 
autoreactive lymphocytes, loss of self-tolerance, and subsequent attack of bodily organs and 
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tissues61,62. Autoreactive lymphocytes (B and T cells) aberrantly recognize self-proteins as 
autoantigens, stimulating an inflammatory response and resulting in systemic or organ-specific 
attack. Common dysfunctional biological pathways underlie autoimmunity as evidenced by 
common genetic associations shared among autoimmune diseases62. However, differences in 
phenotypic manifestations between diseases are largely dependent on the target organ. For 
example, multiple sclerosis attacks the myelin sheath, rheumatoid arthritis targets synovial 
tissue in joints, and type I diabetes affects beta cells in the pancreas61,63. In AA, the target organ 
is the hair follicle. However, the precise autoantigens within the HF that are responsible for 
immune activation and disease precipitation remain unknown.  
Sudden Whitening of the Hair 
An interesting clinical phenomenon is observed in a 
subset of AA patients, known as canities subita, or Marie 
Antionette Syndrome. Historical accounts of Marie Antionette 
on the eve of her execution in 1793 reported ‘sudden 
whitening’ of her hair. Many clinicians attribute this striking 
observation to the acute onset of AA, in which it is postulated 
that AA immune cells preferentially attack the pigmented HFs 
and spare the white hairs, giving the appearance of ‘sudden 
whitening’. Reports of AAP patients with residual white hairs 
in lesional areas of hair loss supports this hypothesis. 
Additionally, many AA patients who begin to recover initially 
regrow white hairs, before the hair shaft fully re-pigments. As 
a result, these observations have fueled the long-standing 
hypothesis that the pigment-producing cells, melanocytes, are the HF-specific targets in AA 
autoimmune attack. In support of this theory, histopathology of AA skin biopsies reveals 
dysmorphic hair bulb melanocytes (Figure 6, discussed in more detail in section 1.6)64. The 
Figure 6 | Aberrant AA 
melanocytes. Melanocyte cell 
death (marked by PM-degenerating 
pigment cell) in hair follicle of AA 
patient. Healthy melanocytes are 
denoted with NM (normal healthy 
melanocytes). HF structural 
components are annotated as 
follows: MX=matrix, DP=dermal 





preferential attack of pigmented hair follicles in AA is an unanswered observation in the field, 
and the mechanism underlying this phenomenon has yet to be explained. I will address this 
question in Chapter 2.   
Genetic Architecture of AA 
As a complex disease, both environmental and genetic factors contribute to the risk of 
developing AA. Environmental triggers such as trauma, infections, the gut microbiome, and 
emotional stress are all correlated with disease onset and progression55,65,66. In addition to 
possible environmental triggers, AA also has a strong genetic component, as evidenced by 1) 
familial aggregation of increased disease incidence; 2) twin concordance rates of 42-55%; 3) 
heritability with a 10-42% incidence of AA between relatives; and 4) examples of early onset 
cases of AA in childhood, all of which strongly indicate a heritable component of disease. 
Individuals with family members diagnosed with AA are at an increased risk of developing AA 
themselves compared to the general population. A study of 206 patients and 3654 relatives 
concluded that lifetime risk of AA raises to 7.8% in first-degree relatives, compared to 2.1% in 
the general population67. Studies that investigated the occurrence of disease in monozygotic 
and dizygotic twins also provide insight into the heritability of AA. Due to the identical genetic 
makeup of monozygotic twins, a trait that is more prevalent in monozygotic compared to 
dizygotic twins supports a genetic contribution to disease. The first twin study in AA reported a 
concordance rate of 55% in monozygotic twins versus 0% in dizygotic twins68. The same group 
subsequently performed a larger twin study and found concordance rates of 42% in 
monozygotic twins versus 10% in dizygotic twins69. Due to the finding that monozygotic 
concordance rates were less than 100%, it is postulated that the environmental factors influence 
a portion of disease risk and supports a role for non-genetic components in AA development. 
Nonetheless, the 42-55% monozygotic concordance rate supports a strong genetic component 
in AA.  
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A linkage analysis study from our lab confirmed genetic etiology of disease in a genome-
wide search for susceptibility loci in 20 AA-affected families34. This study found four 
susceptibility loci on Chr. 6, 10, and 16, with the strongest linkage on Chr. 18. To further 
understand the genetic architecture of AA, our lab initially performed a GWAS and meta-
analysis in 3,253 AA cases and 7,543 controls. These genetic studies successfully yielded 
common SNP associations in at least 14 risk loci in AA70,71. As seen in other autoimmune 
diseases, most risk loci were shared among other autoimmune diseases (HLA, MICA, IL21/2, 
IL2RA, CTLA4, PRDX5, IKZF4, LRRC32, SH2B3/ATXN2, ACOXL/BIM, 
CIITA/CLEC16A/SOCS1, IL13/4). However, two associated regions (STX17, ULBP3/6) 
harbored genes that were specific to AA and had not been associated with other autoimmune 
diseases 70,71. Interestingly, both genes were also expressed in the target organ, the HF70. 
Genes expressed in the HF and specific to AA pathogenesis were prioritized as candidates for 
investigating the mechanisms of organ-specific attack in AA. Genes implicated in HF biology 
offered potential insight for understanding the elusive AA autoantigen(s) and its role in target 
organ mediated immune attack. As discussed in Section 1.4, GWAS lack the resolution to 
identify causal functional variants in risk loci, therefore, deep sequencing studies and 
experimental assays are necessary for determining the effects of disease-associated variants in 
GWAS-identified loci.  
In Chapter 2, I used targeted sequencing and functional experiments to elucidate the 
function of STX17 in AA pathogenesis.  
Genetic and pathologic implication of STX17 
 Unlike many of the other AA-associated genes discovered in the GWAS, STX17 had not 
been previously implicated in any other autoimmune diseases, suggesting that its disruption 
may play a specific role in the AA target organ, the hair follicle. Syntaxin17 (STX17) was further 
prioritized for functional analysis due to its expression in the HF and previous implication in hair 
color variation. Although not shared among other autoimmune diseases, genetic variation in 
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STX17 was previously associated with differences in hair pigmentation and color72,73. A GWAS 
of 27 human traits identified a SNP (rs9556) in the 3’ UTR of STX17 that was significantly 
associated with human hair color72. Moreover, a duplication in intron 6 of STX17 was identified 
as a causal variant for a premature hair graying phenotype in Lipizzaner horses73. In this breed, 
horses are born with fully pigmented coats and completely lose hair pigmentation and become 
gray before 8 years old. Additionally, the gray horses have significantly higher incidences of 
melanomas. The causal mutation was mapped to a CNV resulting in a 4.6 kb duplication that 
harbors a melanocyte-specific transcription factor, MITF73,74. Melanomas biopsied from gray 
horses expressed higher levels of STX17 and neighboring gene, NR4A3. Interestingly, the AA 
associated-SNP identified by our GWAS fell within the same intron as the duplication with 
reported melanocyte-regulatory effects in horses. The association of STX17 with hair color 
variation was intriguing because of the clinical correlations between AA and the preferential 
attack of pigmented hair follicles. We postulated that variation in STX17 may disrupt hair 
pigmentation biology and result in the aberrant 
inflammatory attack in AA-susceptible individuals. 
 Although previous studies implicated STX17 in 
hair color determination, the functional effect of STX17 
on pigmentation was not further explored. STX17 encodes 
the STX17 protein that was originally characterized by 
its role in the autophagy pathway. Autophagy is a critical 
cellular process that regulates degradation of cellular 
contents and aggregated proteins through the fusion of 
autophagosomes  with lysosomes75. STX17 is a 
member of the soluble N-ethylmaleimide-sensitive factor 
attachment protein receptor (SNARE) protein family that facilitate membrane fusions through 
the complex of Qa-, Qb-, Qc-, and R-SNARE proteins that form helix bundles. STX17 is a Qa-
Figure 7 | Role of STX17 in 
autophagy. The hairpin SNARE protein, 
STX17, contains two transmembrane 
domains (TMDs) that form a hairpin 
structure and aids in localization of 
STX17 to mature autophagosomes to 
facilitate fusion with lysosomes through 
complexes with SNAP-29 and VAMP8. 
LC3 (microtubule-associated protein 
1A/1B-light chain 3) marks isolation 




SNARE protein that traffics to mature autophagosomes to facilitate autophagosomal-lysosomal 
fusion with SNAP-29 (Qbc-SNARE) and VAMP8 (R-SNARE) (Figure 7)75. The majority of 
SNARE proteins are single transmembrane domain (TMD) tail-anchored proteins that are 
initially localized to the ER before trafficking to their target organelle membranes. However, 
SXT17 is unique in that it contains 2 TMDs that form a hairpin structure and are critical for 
selective targeting to the autophagosome membrane (Figure 7)75. This allows specific trafficking 
to mature autophagosomes and accurate regulation of autophagosome-lysosome fusion in the 
autophagy pathway. Since this initial finding, additional biological roles for STX17 in 
autophagosome formation76, mitophagy77 and mitochondrial fission78 have been reported. 
Although a functional role for STX17 in pigmentation has not yet been investigated, multiple 
studies have reported a central role for autophagy in melanocyte (pigment cell) biology. Taken 
together, these findings suggest that multiple aspects of the autophagy and pigment production 
pathways overlap, and that disruption of autophagy function can perturb melanocyte function 
and pigmentation79-83. In Chapter 2, I investigated the functional role of STX17 in pigment 
production and melanocyte biology.  
 
1.6 Hair Follicle Biology 
As the target organ of AA immune attack, hair follicle biology is a primary focus of this 
thesis. The HF is a dynamic mini organ whose intricate and accessible nature make it a unique 
model to study. In this thesis, I focused on how dysfunction in the HF itself primes the organ for 
attack, resulting in subsequent HF destruction and hair loss. The next section outlines normal 
HF structure and biology to understand how genetic disruption of this organ can result in 
autoimmunity. 
Hair Follicle Structure 
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 The hair follicle is an intricate mini-organ that produces mammalian hair, which 
possesses a wide range of evolutionarily conserved purposes including thermoregulation, tactile 
sensing, protection, and social impact84. During 
fetal skin development, epithelial, neural crest, 
and mesenchymal stem cells of the 
neuroectodermal-mesodermal system produce the 
developing HF, which is continually re-generated 
throughout its lifetime85. Each stem cell source 
generates different compartments of the HF: 
epithelial stem cells produce sebocytes of the 
sebaseous glands (SG) and keratinocytes that 
form the epithelial components of the HF 
including the matrix (MX), outer root sheath 
(ORS) and inner root sheath (IRS) (Figure 8). 
Mesenchymal stem cells give rise to fibroblasts 
which comprise the dermal papilla (DP) and connective tissue sheath (CTS) (Figure 8). The 
neural crest cells produce the melanocytes of the hair follicle pigmentary unit (HFPU) which 
resides atop the basement membrane of the matrix, directly above the DP84,85.  
Beginnning at the base of the HF, the bulb region contains the DP, matrix, and HFPU 
(Figure 8). The DP is made up of specialized fibroblasts that regulate the proliferation and 
differentiation of the surrounding matrix cells. A basement membrane separates the DP from the 
matrix86. The matrix is composed of actively proliferating keratinocytes that differentiate to form 
the terminal keratinocyte lineages of the IRS and hair shaft (Figure 8). The HFPU also resides in 
the bulb, above the basement membrane and is composed of melanocytes, which are 
responsible for producing melanin pigment that is deposited into the surrounding matrix 
keratinocytes as they proliferate and differentiate up the hair shaft. Across the widest part of the 
Figure 8 | Hair Follicle Structure. The HF is a 
mini-organ composed of many different 
compartments, regions, and cells types.  The 
bulb region, suprabulbar, isthmus, and 
infundibulum span the HF from the base to the 
opening at the epidermis. Concentrically from 
inner to outer the layers of the hair follicle are 
the hair shaft (medulla, cortex, cuticle), IRS 
(IRS cuticle, Huxley’s layer, Henle’s layer, 
companion layer), ORS, CTS. The DP and 
matrix reside in the bulb. Dashed box indicates 




bulb spans the Line of Auber, a critical separation between proliferating, undifferentiated 
keratinocytes below the line and diferentiated terminal keratinocytes above the line87. 
 The differentiated keratinocytes of the matrix give rise to the concentric layers that 
constitute the hair shaft and IRS. Each of the individual layers are differentiated by their unique 
expression of different keratin proteins (discussed in more detail in section 1.5.2)84. The hair 
shaft is made up of 3 layers that constitute the external hair fiber that emerges from the scalp. It 
is composed of highly keratinized terminally differentiated cells that are responsible for its 
enormous tensile strength. The medulla and the cortex make up the inner layers of the shaft, 
which are surrounded by the cuticle, the outermost shaft layer which protects the inner layers 
from environmental injuries and anchors the growing shaft to the HF unit (Figure 8)84. The 
cuticle possesses a scaled texture that allows interlocking with the IRS cuticle during growth. 
The IRS is made up of 4 consecutive layers consisting of the IRS cuticle, Huxley’s layer, Henle’s 
layer, and the companion layer. The companion layer loosely binds to the stationary ORS, 
allowing the IRS and hair shaft to grow upward towards the skin epidermis84. The ORS is the 
outermost epithelial layer that harbors the bulge, a reservoir of epithelial HF stem cells (Figure 
8, dashed box). Finally, the connective tissue sheath envelops the entire epithelial unit of the 
HF. 
These layers extend concentrically from the bulb region, up the HF towards the skin 
epidermis (Figure 8). Ascending the hair shaft, the HF structure consists of the bulb, the 
suprabulbar region, the isthmus, and the infundibulum (Figure 8). The upper part of the hair 
follicle (the infundibulum and isthmus) is static and non-cycling while the suprabulbar and bulb 
region are constantly regenerating during the hair cycle (discussed in more detail in section 
1.6.4)84. The isthmus contains the bulge which houses HF stem cells responsible for providing 
the HF with its regenerating capacity (Figure 8, dashed box). Damage or loss of the bulge 
results in irreversible hair loss due to the inability of the HF to produce the necessary epithelial 
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keratinocyte and melanocyte stem cells required for generating a new follicle88. The melanocyte 
and keratinocyte cell properties will be discussed in further detail in the next sections. 
Keratinocyte Cell Biology 
Keratinocytes are epithelial cells that make up approximately 95% of the skin epidermis 
and are characterized by their expression of keratin proteins during differentiation90,91. Keratins 
are intermediate filaments (IF) that provide structure and stability to the cells through 
heterodimerization and bundling89. Keratin heterodimers from tetramers that are surrounded by 
a network of keratin associated proteins, which interact 
with the keratin tetramers through disulfide bridges92. 
Heterodimers are composed of one type I and one type II 
keratin. Type I keratins (K9-K28, K31-K40) are smaller in 
size (40-56.5 kDa) and acidic in charge. Type II keratins 
(K1-K8, K71-K86) range from 53-67 kDa and are neutral 
to basic in charge89. Interestingly, a subset of 
keratinocytes produces hair specific keratins that are 
exclusively expressed in the HF and the nail matrix/bed. 
The hair specific keratins are further sub-divided into 
“soft” keratins (type I K25-K28, type II K71-74) expressed 
in the epithelial root sheaths, and “hard” keratins (type I 
K31-40; type II K81-86) in the hair shaft and nails89. The 
hard keratins possess a higher sulfur content, allowing for 
increased cross-linking capabilities89. The increased 
disulfide bonds and cross-linking strengthen the stability 
and structure of hard keratin interactions, which are responsible for the tensile strength of the 
hair fiber92,93. Epithelial and hair keratins exert highly specific expression patterns within the HF, 
thereby defining the different layers and compartments (Figure 9). 
Figure 9 | Keratin expression in the 
HF. Both type I and type II keratins are 
expressed in each layer of the HF to 
form strong IF bundles through cross-
linking and heterodimerization with one 




The hair specific keratins are intriguing antigenic candidates for AA immune attack since 
they could provide a potential explanation for the hair-targeted attack that is characteristic of 
disease. Approximately 25% of AA patients present with a “pitting” nail abnormality as a 
symptom, which is more common in severe forms of disease94. Since hair keratins are 
expressed in both the nail matrix and HF, a hair specific keratin autoantigen would explain the 
affected nail and hair sites that are observed in disease. In support of this, previous work found 
that AA antibodies recognized HF keratins, and specifically that AA patient serum reacted with 
human HF proteins of size 44/46 kDa and 60 kDa95. Furthermore, 44/46 kDa keratin proteins 
were immunoprecipitated from murine AA serum but not control. Interesting to note, 60-kDa 
keratins were present in both AA and control serum95. These findings suggest that a 44/46 kDa 
hair keratin(s), whose size is characteristic of type I keratins, possess antigenic qualities in AA. 
Although follow up work has not elucidated the precise antigen(s), type I hair keratins are 
attractive candidate proteins. 
Melanocyte Biology 
Melanocytes are neural crest-derived cells responsible for pigmenting the skin and hair. 
They are found in the basal layer of the epidermis as well as the HF, and possess dendrite-like 
projections that interact with surrounding keratinocytes and deposit pigment96,97. Epidermal 
melanocytes are smaller than HF melanocytes, with shorter dendrites and smaller 
melanosomes, and one melanocyte pigments approximately 30-40 surrounding keratinocytes96-
98. The HF melanocytes are distinct from skin melanocytes in that they 1) regenerate with each 
new hair follicle; 2) pigment approximately 5 keratinocytes; and 3) are larger in size with larger, 
more pigmented melanosomes98. Despite these differences, the current dogma maintains that 




Melanin is a chemo- and photoprotective pigment that supports cellular health through 
UV light absorption and free radical scavenging96,98,100. However, the production of melanin itself 
results in toxic oxidative intermediates that must be tightly regulated in specialized organelles 
called melanosomes100. Melanosomes 
are lysosome-like organelles that 
undergo four stages of maturation during 
melanogenesis, the process of melanin 
production. First, vacuolar early 
endosomes form non-pigmented Stage 1 
melanosomes (Figure 10). PMEL17 
(premelanosome protein; also known as 
gp100/SILV) is a critical structural 
transmembrane protein that is sorted to 
Stage 1 and subsequently cleaved and 
released from the membrane into the 
melanosomal lumen100,101. Melanosome 
protein, MART1 (Melanoma antigen 
recognized by T cells 1) complexes with 
PMEL17 in the ER/early Golgi to 
regulate PMEL17 trafficking, stability, 
and processing102. After PMEL17 
cleavage and processing, PMEL17 forms amyloid fibrils that striate the melanosome, a hallmark 
characteristic of stage 2 (Figure 10). In the Stage 2-to-3 transition, the melanin biosynthetic 
enzymes Tyrosinase (TYR), tyrosinase-related protein 1 (TYRP1), and tyrosinase-related 
protein 2 (TYRP2) are trafficked to the melanosome. TYR is the rate-limiting enzyme in melanin 
production that catalyzes the reaction to produce melanin pigment99,100. In stage 3, melanin 
Figure 10 | Melanogenesis Pathway. Melanogenesis 
produces pigment by undergoing four melanosome stages 
of maturation within the melanocyte. PMEL17 and MART1 
sort to early endosomal stage 1 melanosomes, where 
PMEL forms fibrils for stage 2. Enzymatic proteins TYR 
and TYRP1 are trafficked to maturing stage 2. In stage 3, 
pigment is produced and deposited on the fibrils. In stage 
4, melanosomes are fully pigmented and deposited into 
surrounding keratinocytes. αMSH= α-melanocyte-
stimulating hormone; AP= adaptor protein; BLOC= 
biogenesis of lysosome-related organelles complex; 
cAMP= cyclic adenosine monophosphate; MART= 
melanoma antigen recognized by T cells; MC1R= 
melanocortin 1 receptor; MITF= microphthalmia-
associated transcription factor; PMEL17= premelanosome 
protein; TYRP1= tyrosinase-related protein 1. (Adapted99) 
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granules are deposited on the PMEL fibrils, and in stage 4, the melanosomes reach full 
maturation and pigmentation (Figure 10). After stage 4 maturation, melanosomes undergo 
anterograde transport to the dendritic projections where they are deposited into the surrounding 
keratinocytes (Figure 10). The melanogenesis pathway is regulated both externally (UV light) 
and internally (keratinocytes-melanocyte crosstalk). Keratinocytes produce α-melanocyte 
stimulating hormone (αMSH) that interacts agonistically with melanocyte membrane receptor, 
melanocortin 1 receptor (MC1R) (Figure 10)99. MC1R signaling stimulates the downstream 
cAMP pathway which induces transcription of melanocyte-specific transcription factor, MITF 
(microphthalmia-associated transcription factor). MITF is a master regulator of melanocyte 
processes and subsequently regulates transcription of critical melanosome proteins, such as 
TYRP1, TYRP2, TYR, MART1, and PMEL.  
As mentioned in section 1.5, melanocytes are also postulated to be potential targets of 
AA autoimmune attack. Clinical evidence (previously discussed) such as canities subita and 
dysmorphic follicular melanocytes in AA HFs suggest that autoreactive CD8+ T cell infiltrate 
targets follicular melanocytes for destruction in AA. Moreover, the autoreactive lymphocytes 
infiltrate the HF bulb region, where HF melanocytes reside. Melanogenesis also exclusively 
occurs during the growth phase (anagen) of the hair cycle, which is precisely when AA attack 
occurs (discussed in more detail in next section). Additional studies investigating melanocyte 
proteins further support the role for melanocyte antigens in AA pathogenesis. Firstly, the highly 
immunogenic nature of melanocyte antigens is supported by the CD8+ T cell recognition of 
PMEL, MART1, TYR, TYRP1, and TYRP2103. Specifically, PMEL, MART1, and TYR induced T 
cell activation and were implicated as auto-antigens in another skin autoimmune disease, 
vitiligo104,105. In AA, patient serum reacted with a wide range of epidermal and HF melanocytic 
proteins97. HF-specific melanocyte proteins that were recognized by AA serum were identified 
as 52-,67-, and 127 kDa in size97. Further elucidation of melanocyte antigens in AA revealed 
PMEL, MART1, and TYRP2 as capable of activating T cells in AA, supporting a potential role for 
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these proteins as AA autoantigens. Collectively, these findings point to a role for melanocyte-
specific proteins as candidate autoantigens and possible contributors to disease pathogenesis. 
Taken together, melanocytes are present at the right time, right place, and induce the right 
response to be feasible targets for inciting AA autoimmunity.  
Hair cycle and Immune Privilege 
The hair follicle is the only organ that continually regenerates throughout its lifetime. In 
order to accomplish this, the HF undergoes three stages of the hair cycle: anagen (growth), 
catagen (regression), and telogen (quiescence) (Figure 11). As the HF enters the last stage of 
telogen, a new follicle begins anagen in its place, shedding the previous follicle. Anagen, the 
growth stage, has the longest duration, lasting 1-8 years for human scalp hairs59. During this 
time, the shaft is continually growing, and 
the HF matrix is actively proliferating and 
undergoing melanogenesis. Next, the HF 
enters the catagen stage which is 
characterized by HF regression driven by 
apoptosis. Although catagen is 
considered to be mostly a result of 
apoptosis-mediated cell death, other cell 
death mechanisms and processes such 
as autophagy may also be implicated in 
the anagen-to-catagen transition106.  
During catagen, the lower dynamic region 
of the HF (bulbar and suprabulbar) recedes to the upper non-cycling HF region (Figure 11)93. 
After catagen, the HF enters telogen, a stage of quiescence, following which HF stem cells in 
the bulge activate to produce a new anagen HF59,93. 
Figure 11 | Hair Cycle and AA attack. HFs undergo a 
hair cycle consisting of anagen (growth), catagen 
(regression), and telogen (rest). In AA, immune attack 
occurs during anagen, while melanogenesis is also 
active. Lymphocytic infiltrate localizes to the bulb and 
consists of NK cells, CD8+ T cells, CD4+ T cells, mast 
cells, and dendritic cells. As a result, the anagen HF is 




During anagen, the HF is an immune privileged (IP) site, which refers to tissue 
compartments that avoid immune self-recognition. Other IP sites include vital tissues that are 
necessary for an individual’s survival and propagation, such as the testis, fetomaternal placenta, 
blood-brain barrier, and the anterior eye chamber107. Complex mechanisms are necessary for 
maintaining tissue IP including 1) downregulation of MHC class I (molecules for antigen 
presentation to CD8+ T cells); 2) local immunosuppressants such as α-MSH, TGF-β, MIF, and 
IL-10; 3) immunoinhibitory signals (CD200 and VIPR); and 4) repression of antigen presenting 
cells (APC)58,107. In AA, IP collapse during anagen is considered to be an initial step in disease 
pathogenesis. The immunogenic nature of melanocyte antigens is postulated to be a driving 
factor in IP collapse of AA HFs58,107. Melanocytes also possess the capability to process and 
present MHC class II antigens96. Following IP collapse in the AA HF, immunoinhibitory signals 
are downregulated and HFs express MHC class I and II molecules aberrantly58. As a result, 
immune infiltrate consisting of APCs, CD4+ T cells, and CD8+ T cells invade the bulb region of 
the anagen HF (Figure 11). 
HF and Skin Hereditary Disorders 
 Dermatologic conditions affecting the skin and hair are caused by both monogenic and 
polygenic types of disease. Genetic mutations in keratins contribute to a wide range of 
monogenic skin disorders including epidermolysis bullosa (K5, K14), epidermolytic 
hyperkeratosis (K1, K10), epidermolytic palmoplantar keratoderma (K9), ichthyosis hystrix (K1), 
and white sponge nevus (K4, K13) (Figure 12)108. Mutations in both type I and type II keratins 
are causal in these skin diseases and a majority of pathogenicity is a result of missense 
mutations108. Monogenic keratin mutations also result in pathogenic hair disorders including, 
monilethrix (K81, K83, K86), pseudofolliculitis barbae (K75), and ectodermal dysplasia of hair 
and nail type (K85) (Figure 12)109. Interestingly, all of the monogenic hair keratin disorders have 
been attributed to mutations in only Type II hair keratins.  
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Human Disorder Type I Keratin Type II Keratin
Epidermolysis bullosa simplex (AD) K14 K5
Epidermolysis bullosa simplex (AR) K14
EBS with migratory circinate erythema K5





Epidermolytic hyperkeratosis (AD) K10 K1
Epidermolytic hyperkeratosis (AR) K10
Ichthyosis hystrix Curth-Macklin K1
Diffuse non-epidermolytic PPK K1
Palmoplantar keratoderma with 
tonotubules
K1




Pachyonychia congenita type I K16 K6a
Pachyonychia congenita type II K17 K6b
Steatocystoma multiplex K17





Ectodermal dysplasia of hair and nail 
type
K85
Meesmann corneal epithelial 
dystrophy
K12 K3
White sponge nevus K13 K4
Familial cirrhosis
K18a K8a
Inflammatory bowel disease K8a
The keratin protein family contains three domains consisting of the head, the alpha-
helical rod (1A, 1B, 2A, 2B subdomains), and the tail domain (Figure 12). The rod domain is 
made up of 310 amino acids that are critical for heterodimerization and IF formation108. The vast 
majority of monogenic keratin disorders result from mutational hotspots at the terminal ends of 
the 1A and 2B rod subdomains in both type I and type 
II keratins108 (Figure 12, orange subdomain). In type II 
keratins, disease-causing mutations have also been 
annotated in the head and tail domains110. The 
resulting proteins generated from these mutations 
have functional defects in heterodimerization causing 
fragile keratin networks and subsequent weak tissue 
integrity108,110.  
 In addition to a wide range of monogenic 
keratin disorders, mutations in melanocyte genes also 
give rise to Mendelian pigmentary skin disorders. As 
discussed in the previous section, melanogenesis is a 
tightly regulated process. Therefore, melanocyte 
dysfunction caused by single gene mutations result in 
both hypo- and hyper-pigmentary skin disorders. 
Hypopigmentary disorders include piebaldism, 
Waardenburg syndrome, oculocutaneous albinism, 
Hermansky-Pedlak syndrome, Chediak-Higashi syndrome, and Griscelli Syndrome. Although 
some monogenic hypopigmentary diseases are caused by mutations in signaling genes non-
specific to melanocytes (i.e. KIT in piebaldism), particularly interesting are the monogenic forms 
of oculocutaneous albinism that are caused by the mutations in the melanogenesis pathway 
genes, TYR, OCA2, TYRP1, SLC45A2, and GPR143. On the other end of the pigmentation 
Figure 12 | Keratin disorders and 
domains. Table of human keratin 
disorders and the mutations in keratin type 
I and II proteins attributed to disease. 
Structure of keratins consisting of a head 
domain, a rod domain (1A, 1B, 2A, and 2B 
separated by linker sequences (L)) and tail 
domain. (Adapted108)  
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disease spectrum, hyperpigmentary disorders such as neurofibromatosis 1, dyskeratosis 
congenital, Naegeli-Franceschetti-Jadassohn Syndrome (NFJS), or Dowling-Degos disease, are 
not caused by mutations in the melanocyte-specific genes. Interestingly, NFJS and Dowling-
Degos disease are actually caused by mutations in K14 and K5, respectively109. Both diseases 
share a common mesh-like pattern of hyperpigmentation of the skin. The involvement of keratin 
genes in these similar pathologies suggests dysfunction in keratinocyte retention of 
melanosomes, rather than skin melanocytes ability to produce melanin pigment. 
 Complex dermatologic diseases include common disorders that affect either the skin or 
the HF. Other complex forms of alopecia (hair loss) include androgenetic alopecia (the most 
common), cicatricial alopecia, telogen effluvium, and lichen planopilaris. AA is unique from 
these other forms of hair loss because of its autoimmune disease mechanism. Systemic lupus 
erythematosus (SLE), psoriasis, atopic dermatitis, systemic sclerosis, vitiligo, pemphigus 
vulgaris and Sjogren’s syndrome are similarly all inflammatory/autoimmune diseases that result 
in varying degrees of skin inflammation and can be distinguished by their unique phenotypes111. 
For example, vitiligo targets and destroys epidermal melanocytes resulting in a depigmentation 
phenotype in demarcated skin regions. Distinctly, pemphigus vulgaris attacks the epithelial cell 
adhesion proteins, resulting in painful blisters and lesions on the skin and mucus membranes112. 
Genetic studies have revealed substantial genetic overlap between autoimmune diseases, 
including the CTLA4, IL2RA, IL23R, IL2/21, STAT4, and PTPN22 loci113. Genes that are not 
shared amongst inflammatory disorders are postulated to explain the disease-specific targets of 
autoimmune attack unique to each skin autoimmune disease. This thesis will focus on the 
functional interrogation of two HF-genes (STX17 and KRT82), and how genetic disruption of 




1.7 Focus of Thesis 
In this thesis, I utilized two main genetic approaches to identify variants associated with AA: 
targeted sequencing and WES. WES allowed us to perform an unbiased search across the 
entire exome to identify genes harboring rare variation associated with AA, while targeted 
sequencing provided a hypothesis-driven approach that allowed us to interrogate all variants, 
coding and non-coding, in a previously identified GWAS locus associated with AA.  
First, we focused our targeted sequencing analyses on loci harboring 1) genes expressed in 
the hair follicle; and 2) genes specific to AA autoimmunity. This allowed us to focus on end-
organ target genes whose disruption was potentially unique to AA disease pathogenesis. Using 
this strategy, we sequenced a 550 kb region spanning Syntaxin17 (STX17) and its associated 
LD block in 849 AA cases. We identified 35 variants that defined a risk haplotype responsible for 
driving the GWAS association. Using a combination of multi-dimensional analyses and in silico 
algorithms, we annotated 32 variants that were significantly associated with AA and 
downregulated STX17 expression in the skin of AA patients. Interestingly, two variants resided 
in the STX17 promoter region and one variant fell in a melanocyte-specific enhancer. I followed 
up this discovery by determining the functional role of risk gene, STX17 in melanocyte biology 
and AA disease pathogenesis. 
Secondly, to uncover rare unknown risk variants contributing to AA, we performed WES 
on the same 849 AA cases and compared these results to 15,640 controls. Gene-level burden 
tests and collapsing analyses identified the Keratin 82 (KRT82) gene as the highest associated 
AA gene, achieving genome-wide significance (p<6.7E-07), in 3 rare damaging collapsing 
models. Interestingly, KRT82 is a hair-specific type II keratin that is expressed exclusively in the 
hair shaft cuticle during the anagen (growth) stage of the hair cycle. KRT82 is also a HF-specific 
gene without any previously reported associations with other autoimmune or Mendelian 
diseases. In Chapter 3, we used WES methods, gene burden analyses, and functional 
interrogation to understand a potential new mechanism of hair shaft defects and their 
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contribution to AA pathogenesis. Our use of WES and gene collapsing analyses for the first time 
in AA illustrated the ability of these approaches to identify rare disease associations in 
functionally relevant risk genes using a moderate sequencing cohort size.  
Importantly, I defined two new disease pathomechanisms driving AA susceptibility that 
implicated the HF itself in disease. Up to now, most of the therapeutic approaches in AA have 
focused on targeting the immune response and clearance of pathogenic T cells. The findings 
presented in this thesis suggest that restoring the integrity of structural elements in the HF itself 
may represent new therapeutic targets that could be useful in combination with 
immunomodulation. This thesis centered around the use of sequencing strategies to functionally 
interrogate the role of genetic perturbation in the target organ, HF, and how its dysfunction 











Chapter 2 Functional genomics analysis of STX17 in AA 
revealed a novel role in melanocyte function 





Historical accounts of Marie Antionette described the rapid whitening of her hair in the 
days prior to her execution in 1793114. Since then, both historical and clinical case reports have 
outlined the occurrence of a phenomenon known as canities subita, or sudden whitening of the 
hair114,115. Many dermatologists attributed this phenomenon to Alopecia Areata (AA), a highly 
prevalent autoimmune disease that is characterized by aberrant CD8+ T cell attack of the hair 
follicle (HF), resulting in patchy (AAP) or widespread hair loss of the scalp (AT) or body (AU)114-
116. In canities subita, the immune cells preferentially attack the pigmented hair follicles, sparing 
unpigmented follicles from death and eliciting a deceptive appearance of sudden whitening of 
the patient’s hair64,117.  In AA, pigmented hairs with active melanocytes, pigment-producing cells, 
are aberrantly targeted for destruction by immune cells, while white hairs without functionally 
active melanocytes are spared. Consequentially, a widely accepted hypothesis in the 
dermatology field is that the pigment-producing melanocytes are the target of AA attack64,117. 
The precipitating AA antigen is still not fully elucidated; however, convincing evidence suggest 
melanocytic antigens as potential targets for AA autoimmune activation.  
To further define the role of melanocyte antigens and the preferential attack of 
pigmented hair follicles in AA, we investigated the 14 previously-identified GWAS risk loci for 
pigment-related genes that may explain this phenomenon70,71. Of the 14 risk regions, a locus on 
chromosome 9 harbored a gene that was previously implicated in hair pigmentation. Syntaxin17 
(STX17) encodes a protein (STX17) with a well-defined role in autophagy through mediation of 
autophagosome-lysosome fusion and autophagosome formation at mitochondria-ER contact 
sites75,76. A possible new role for STX17 in pigment regulation was identified in a recent genetic 
study that investigated 27 traits in ~415,000 subjects, and found a SNP in the 3’ UTR of STX17 
that was significantly associated with human hair color72. Prior to identification of the STX17 
association with human hair color, a 4.6 kb duplication in intron 6 of STX17 was identified as a 
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causal mutation for premature graying in Lipizzaner horses73. However, the mechanism 
underlying the relationship between STX17 variants and hair color/graying remains undefined.  
The significant associations of STX17 in both hair pigmentation and AA suggested that 
STX17 function may be a potential genetic link between AA pathogenesis and the targeted 
attack on pigmented HFs70-73. In this study, we utilized a targeted sequencing fine mapping 
approach to identify significant variant(s) driving the GWAS association between the 550 kb 
STX17 region and AA risk. Through the use of in silico methods, multi-dimensional datasets, 
and in vitro assays, we investigated the role of STX17 in pigmentation and the impact of its 
disruption on AA susceptibility. 
 
2.2 Targeted genomic sequencing of the STX17 locus identified 35 non-coding risk 
variants 
 GWAS is a useful tool for elucidating part of the genetic architecture of complex 
disorders by identifying common variants associated with a disease or trait of interest. However, 
fine mapping of the associated regions is necessary to determine the genetic variants that are 
driving the GWAS signal118. GWAS test only a portion of common variants present in the human 
genome, resulting in the possibility of causal SNPs not being directly interrogated using this 
method.  The surrounding SNPs residing on a given linkage disequilibrium (LD) block are 
disproportionately inherited together, allowing identification of associated regions but incapable 
of distinguishing the true risk variant(s) from variants carried along on the same risk haplotype. 
As a result, follow-up fine mapping of association regions is necessary for identifying the causal 
variant(s). Our GWAS identified an association of a SNP (rs10760706) in intron 6 of STX17 with 
AA risk (p=3.6E-07)70. To resolve the potential variants contributing to this association, we 
performed targeted sequencing of a 550 kb region including the STX17 gene and surrounding 
LD block (chr9:102560179-103110179; hg19) (Figure 13). We sequenced both coding and non-
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coding regions given that the GWAS SNP, rs10760706, is an intronic variant and 90% of 
disease-causing variants in autoimmune diseases are non-coding20. 
 Sequencing, alignment, variant calling, and quality control were performed as previously 
described119 in 849 AA cases and 62 controls of European descent. Following our analytic 
pipeline (Figure 13), we identified 5,841 variants in AA cases across the 550 kb region. In order 
to prioritize variants and define those responsible for driving the association with AA, we 
identified a region (chr9:102669557-103053538) linked with our GWAS SNP, whose boundaries 
were defined by variants with r2 0.4. 4,037 AA variants fell within these boundaries and, 
therefore, we further defined a LD block of interest by variants in strong linkage disequilibrium 
(LD) with our GWAS SNP, rs10760706 (r2 0.8).  This resulted in a region spanning 
chr9:102669557-102734130 and contained 693 AA variants. Of the 693 variants in the region, 
35 were commonly inherited with rs107060706 (r2>0.8), thus defining our risk haplotype. We 
found that the 35 variants defined two common haplotypes120, one of which contained the 
GWAS risk allele (C) and was present in 26.3% of the European (CEU) population (Figure 14). 
Interestingly, the SNP identified in the hair color GWAS (rs9556) was simultaneously carried on 
this haplotype72 (Figure 14-15a). Additionally, the AA risk haplotype carrying the 35 variants 
spanned the same region as the STX17 4.6 kb duplication previously identified as causal for 
regulating premature hair greying in Lipizzaner horses (Figure 15a)73.  
Next, we tested all of the sequencing variants (n=465) that fell within the haplotype-
defined boundaries (chr9:102669557-102734130) and compared case allele counts to quality-
controlled allele data available from the gnomAD database (Genome Aggregation Database)121. 
We analyzed significant associations using Non-Finnish European (NFE) controls from gnomAD 
and found that 33 of the 35 variants that defined the risk haplotype were significantly associated 
with AA after accounting for multiple testing (α=0.05/465=1.08E-04). The other two variants 
(rs10124366 and rs10116142) reached nominal significance. Other variants within the region 
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that were not in strong LD with rs10760706 and did not define the risk haplotype demonstrated 
weaker association with AA (Figure 15b, Table 1). This suggested that the risk haplotype 
carrying 35 variants was responsible for driving the GWAS association signal, and the 33 
significantly associated variants were contributing to AA risk. The discovery that the AA risk 
haplotype included a variant previously reported to be associated with hair color supported the 
hypothesis that the disruption of hair pigmentation may play a causal role in AA and STX17 
could be a critical mediator of that disease mechanism.   
 
2.3 eQTL analysis identified 32 significantly associated functional variants 
 Given that all of the SNPs that defined our risk haplotype were noncoding, and that most 
common risk variants are non-coding20,122, we next leveraged multi-dimensional datasets made 
available by consortiums such as ENCODE and GTEx22,123. Expression Quantitative Trait Loci 
(eQTLs) are a particularly useful annotation for identifying meaningful regulatory effects of non-
coding variants, due to their direct integration of genotype alleles and gene expression levels in 
a given cell or tissue type26. Previous expression data from our lab reported a significant 
decrease of STX17 in the scalp skin of AA patients compared to controls (p=3.08E-04)124. 
However, the other four genes (NR4A3, ERP44, INVS, TEX10) located in this 550 kb region 
were not differentially expressed in AA. As a result, we postulated that STX17 gene expression 
had a potential role in disease pathogenesis and investigated the functional effects of these 35 
variants on STX17 gene expression levels in skin. 
We used human tissue expression and genotype data from the GTEx portal and 
analyzed eQTL effects of each significantly associated risk haplotype variant on the expression 
of STX17 in the skin, the target organ in AA, and found that all 35 SNPs were significant eQTLs 
in the skin (Table 1). To test whether these regulatory effects were relevant to AA, we used a 
multi-dimensional data set that integrated genetic data with expression data from lesional scalp 
samples in 41 AA patients. We tested for association of genotypes with STX17 expression 
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levels in the skin, and assessed significance using a pairwise t-test with FDR (false discovery 
rate) correction and confirmed that 33 of the 35 variants on the risk haplotype significantly 
downregulated the expression of STX17 in lesional (hair loss) AA skin biopsies. Nominally 
associated rs10124366 and hair-color SNP rs9556, did not achieve statistical significance for 
genotype-dependent effects on expression. However, both were trending towards decreased 
expression of the risk alleles. Interestingly, rs10116142 reached eQTL significance even though 
it was not significantly associated with AA. Taken together, we identified 32 variants on the risk 
haplotype that were significantly associated with AA and had a functional effect on skin 
expression. While only homozygous carriers of the risk alleles expressed significantly reduced 
levels of STX17 in the scalp skin, trending decreased expression levels of the heterozygotes 
suggested that the effect may be dominant, although a larger sample size would be needed to 
establish significance (Figure 16). AA GWAS SNP, rs10760706, was one of the 32 variants 
identified as a significant skin eQTL. Using this approach, we annotated a functional effect of 32 
sequencing variants that not only significantly associated with AA, but also, significantly reduced 
expression of STX17 in the scalp of AA patients.  
Because these 32 SNPs are in high LD, we next sought to identify the genetic 
mechanism regulating expression levels of STX17. This would allow us to distinguish regulatory 
variant(s) that result in dysregulation from those that appear to effect regulation simply because 
they are being carried along a shared haplotype. In silico algorithms are useful in predicting 
variants that fall in regulatory regions of specific cell types and likely exerting regulatory 
consequences cell-specific expression. The Functional Latent Dirichlet Allocation model (FUN-
LDA) predicts functional effects of every genomic position in 127 human cell and tissue types, 
including the three skin cell types: melanocytes, keratinocytes, and fibroblasts24. By 
incorporating H3K4me1, H3K4me3, H3K9ac, H3K27ac histone modifications and DNase 
hypersensitivity sites, the algorithm provides a reliable and accurate predictive score of 
regulatory effects (scale of 0-1) for each position of the genome. Integrating the FUN-LDA 
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model with our risk haplotype variants, we identified a single SNP, rs7039716, that was 
predicted to be functional in all three skin cell types (Figure 17a). This SNP falls in the first intron 
of STX17 in the 5’ gene end. FUNLDA regulatory peaks at the 5’ gene end and present in all 
cell datasets are indicative of promoter regions, predicting the presence of rs7039716 in the 
STX17 promoter (Figure 17a). Further interrogation of this predicted regulatory SNP using data 
extracted from Roadmap chromatin states confirmed that rs7039716, in addition to rs2416935, 
fell in active transcription start sites (TSS) in primary melanocytes, keratinocytes, and fibroblasts 
(Figure 17b). Interestingly, melanocyte cells had additional regulatory regions (annotated as 
enhancers by Roadmap) located across the gene that were not present in keratinocytes or 
fibroblasts (blue peaks, Figure 17a; yellow bars Figure 17b). We found that three of the AA-
associated SNPs (rs2416936, rs10760706, rs66799478) fell proximal to melanocyte enhancers 
(<400bp) and one variant resided in a melanocyte enhancer (rs7027813) (Figure 17c). The 
increased frequency of regulatory regions in melanocytes compared to other skin cell types, in 
addition to presence of one of the AA risk variants in a melanocyte enhancer allowed us to 
prioritize melanocyte cells for follow-up functional assays. 
In addition to identifying melanocyte-specific enhancers dispersed across the STX17 
locus, previous findings on preferential attack of pigmented HFs, dysmorphic follicular 
melanocytes in AA HFs, and melanocytic antigens eliciting T cell responses in AA models, 
further supported a role for melanocytes in AA pathogenesis. We found additional evidence for 
a disease-relevant role of melanocytes in AA from our microarray expression data in AA scalp 
biopsies124. Pathway analysis performed using DAVID (Database for Annotation, Visualization 
and Integrated Discovery) identified melanogenesis, a pigment-producing process performed by 
melanocytes, as one of the top 30 most significantly affected pathways in AA, with 30 
melanogenesis genes differentially expressed in AA cases compared to controls (p=7.6E-03) 
(Figure 18). This provided added support for a pathomechanistic disruption of melanocyte 
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function in AA and justified further investigation into the possible role of STX17 in melanocyte 
dysfunction and AA disease. 
2.4 Aberrant expression of STX17 proximal to dysmorphic melanocytes in AA HFs 
 We identified and functionally annotated 32 AA-associated variants that downregulate 
STX17 expression in the skin of AA patients and suggested implication of melanocytes as the 
candidate cell type mediating the genetic association of STX17 with AA using in silico methods 
and published literature findings. Since we previously reported that STX17 expression was 
reduced in AA whole skin, we next wanted to investigate whether the HF and HF melanocytes, 
specifically, exhibited dysregulated STX17 expression in AA patients. In the normal healthy HF, 
we observed heterogenous STX17 expression throughout the hair follicle with a strong 
immunofluorescent (IF) band of expression along the basement membrane outlining the dermal 
papilla (DP) (Figure 19a). The follicular melanocytes, marked by premelanosome protein 
(PMEL), localize to the same region surrounding the DP. However, both nonlesional and 
lesional biopsies from the same AAP patient revealed reduced staining along the basement 
membrane (Figure 19b-c). Additionally, the AA hair bulb melanocytes were dysmorphic and 
displaced, supporting previous observations64. In the nonlesional, non-balding site, we observed 
a large reduction of STX17 along the basement membrane proximal to the melanocytes, which 
displayed disrupted morphology and early detachment away from the DP and into the HF matrix 
(Figure 19b). In the lesional active disease site, the basement membrane STX17 expression 
was almost completely lost with fewer hair bulb melanocytes (Figure 19c). The melanocytes that 
remained in the lesional HF appeared dysmorphic and completely detached from the basement 
membrane surrounding the DP.  Collectively, these findings confirmed aberrant STX17 




2.5 STX17 reduction resulted in melanocyte dysfunction and antigen accumulation 
 Both in vivo findings of dysregulated STX17 expression proximal to dysmorphic 
melanocytes in AA HFs and in silico annotations for melanocyte-specific regulatory regions 
across the STX17 gene locus prompted us to perform functional follow-up analyses in human 
primary melanocytes. Melanocytes pigment the skin and hair through a process called 
melanogenesis, or the production of melanin, a highly oxidative reaction that must be tightly 
regulated in specialized organelles called melanosomes125,126. Melanosome biogenesis occurs 
in four stages and is dependent upon trafficking of specified proteins and enzymes to the 
melanosomal vesicles where melanin is produced, and pigmented organelles are formed. 
Genetic disruption of melanogenesis can lead to a wide range of disorders including 
oculocutaneous albinism, Hermansky-Pudlak syndrome, Charcot-Marie-Tooth disease, and 
vitiligo, another dermatological autoimmune disease126,127.  
 Because melanocyte processes are highly regulated and known disruptions cause other 
diseases, we investigated whether melanogenesis was affected by STX17, and sought to 
determine whether STX17-mediated disruption of melanogenesis was a contributing factor in 
AA risk associated with STX17 variation. Due to our finding that AA risk haplotype variants 
decreased expression in the skin, we used STX17-targeted siRNA knockdown to deplete 
STX17 levels in primary human melanocytes. We found that in the absence of STX17, melanin 
production was impaired indicated by an overall decrease in melanin content compared to 
controls (Figure 20a). This suggested, for the first time, that STX17 played a critical role in the 
melanogenesis pathway. Due to the established role of STX17 in autophagy, we investigated 
whether this observed effect was a result of a newly identified role of STX17 in melanocyte 
function or simply a result of autophagy disruption. To test this, we incubated primary human 
melanocytes with 3 different autophagy inhibitors, 3-Methyladenine (3-MA), Chloroquine (CQ), 
and Bafilomycin A1 (BA1). Interestingly, in the presence of autophagy inhibitors, melanocytes 
exhibited the opposite phenotype as STX17-knockdown and had elevated levels of cellular 
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melanin content (Figure 20b). Taken together, this supported a novel autophagy-independent 
role for STX17 in melanogenesis. 
To further understand the novel role of STX17 in melanogenesis, we investigated 
melanosome biology using electron microscopy (EM). Unexpectedly, we saw equivalent 
numbers of total and late-stage melanosomes (Figure 20c-d). This was surprising to us since 
late-stage melanosomes produce melanin pigment, yet the overall melanin content for STX17- 
knockdown cells was decreased. This suggested that in the absence of STX17, the 
melanosomes could form and mature, however, they were unable to produce melanin pigment 
within the melanosomes as efficiently as controls. Interestingly, the number of early 
melanosomes was significantly decreased in STX17-deficient melanocytes (Figure 20c-d). This 
supported a potential role for STX17 in melanosome biogenesis and early melanosome 
trafficking. Further support of an autophagy-independent role of STX17 in melanogenesis was 
evident by the EM phenotype of BA1-treated melanocytes that appeared strikingly different from 
STX17-depletion conditions with a high concentration of autophagosomes and multivesicular 
bodies as is characteristic of late-stage autophagy inhibition in cells (Figure 20e)128. Taken 
together, STX17 exerts an autophagy-independent effect on early melanosome biology that 
results in an overall reduction in melanin production. STX17-deficient cells were able to 
overcome early melanosome reduction and mature to produce equivalent numbers of late stage 
melanosomes and low levels of melanin, suggesting the presence of a secondary redundant 
pathway that may act in parallel to STX17. We postulated that the reduction of early 
melanosomes may be a result of a trafficking defect, and since early melanosomes are 
responsible for structuring the organelle for melanin deposits, melanin may not be as efficiently 
produced in the absence of STX17 and proper cargo trafficking.  
To further investigate the potential role for STX17 in early melanosome cargo trafficking 
and biogenesis, we interrogated the effect of STX17 loss on levels of early and late stage 
melanosome proteins.  MART1 (Melanoma Antigen Recognized by T-Cells 1) is an early 
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melanosome protein critical for melanosomal structural formation, and TYR (Tyrosinase) is the 
rate-limiting enzyme that is trafficked to late stage III melanosomes to synthesize melanin and 
form pigmented melanosomes99,102,129,130. Since we observed that STX17-depleted cells were 
less capable of producing melanin, we postulated that the proteins necessary for the reaction 
would also be negatively affected, explaining the cell’s inability to efficiently perform 
melanogenesis. We found that late stage protein, TYR, levels were unaltered and that 
surprisingly, early stage protein MART1 levels accumulated in STX17-KD melanocytes (Figure 
20f). Once again, we observed a STX17-KD specific effect, as there were negligible increases 
of MART1 in the autophagy inhibition conditions (Figure 20g). The accumulation of early 
melanosome MART1 protein, decreased number of early melanosomes, and reduced melanin 
content suggested a defect in early melanosome cargo trafficking. The lack of early 
melanosomes and reduced ability to produce melanin was speculatively due to aberrant 
accumulation of MART1 unable to traffic to early melanosomes and regulate proper 
melanosome structure and formation.  Preliminary evidence supports this hypothesis in which 
we observed MART1 and STX17 co-localization at baseline conditions and after melanogenesis 
stimulation with αMSH (Figure 21). However, future work will be needed to pinpoint the precise 
mechanism of STX17 cargo trafficking in melanocytes. Collectively, these findings support a 
novel role for STX17 in melanocyte biology that when disrupted, results in accumulation of key 
melanosome protein, MART1.  
The accumulation of MART1 is particularly interesting as it has previously established 
antigenic roles in cancer and autoimmunity. It was reported as a potential autoantigen in both 
AA and vitiligo, another autoimmune disease that targets epithelial melanocytes104,105,131,132. The 
cellular accumulation of MART1, a protein with auto-antigenic properties could feasibly act as a 
precipitating event for autoimmune attack due to an increase in the cell’s antigenic load. Cellular 
accumulation of a reported antigen in the absence of STX17 provides a mechanism to explain 
how the genetic predisposition to decreased STX17 expression levels impairs melanocyte 
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function and results in the accumulation of antigens recognized by auto-reactive T cells. We 
investigated this hypothesis in vivo and found that patients categorized with low levels of STX17 
expression in the skin had large amounts of follicular CD8+ infiltrate (Figure 20h). In conclusion, 
we found that reduction of STX17 in melanocytes disrupted melanocyte function and caused 
accumulation of melanosome autoantigen MART1 in vitro. Furthermore, in vivo we observed 
that decreased STX17 expression correlated with high CD8+ infiltrate surrounding the HF, a 
pathognomonic characteristic of AA.  
  
2.6 Discussion 
This study outlines the successful integration of regional fine mapping and in silico 
prediction methods in AA to identify a functionally relevant cell type and elucidate a mechanistic 
role of a GWAS-identified gene, STX17, in cellular dysfunction and disease pathogenesis. Using 
targeted sequencing, we identified a risk haplotype of 35 functional variants in the STX17 region 
that was responsible for driving the GWAS-identified disease association. Through 
multidimensional datasets obtained from GTEx and 41 AA patients, we annotated that 32 of the 
significantly associated variants also significantly downregulated STX17 expression in AA skin. 
Using in silico methods, we prioritized three variants as likely causal due to their co-localization 
with regulatory regions, thus distinguishing them from the rest of the haplotype variants that 
were not annotated as regulatory, but rather were just carried along on the same risk haplotype. 
The FUN-LDA model predicted one of these variants (rs7039716) to be likely causal in the 
promoter region of skin cell types, and further suggested that melanocytes may be the 
functionally relevant skin cell type with regions of high predicted regulatory effect in melanocytes 
that were not predicted in fibroblasts or keratinocytes. Roadmap chromatin state data confirmed 
the finding of rs7039716, in addition to another variant (rs2416935) in the transcription start 
sites (TSS) of all skin cell types. Additionally, we annotated one variant (rs7027813) that fell in a 
melanocyte enhancer and three other variants proximal to melanocyte enhancers, allowing us to 
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prioritize melanocytes as the candidate cell type for functional analyses. Interestingly, aberrant 
STX17 expression in vivo correlated with dysmorphic melanocytes in AA HFs. Functional 
studies in melanocytes further revealed a novel autophagy-independent role for STX17 in 
melanin production and melanocyte biology. 
We propose that under normal conditions, STX17 aids in the transportation and delivery 
of early melanosome protein, MART1, to forming melanosomes (Figure 22). MART1 forms a 
complex with PMEL (premelanosome) protein and is necessary for regulating its expression, 
processing, and function in melanosome formation102. After PMEL fibrils form, pigment is 
deposited in the late-stage melanosomes (III and IV) before they are sent into surrounding 
keratinocytes to pigment the growing hair shaft (Figure 22). However, in susceptible individuals 
with the AA risk haplotype, STX17 levels are decreased (Figure 22). Consequentially, 
melanosome protein MART1 is not efficiently trafficked to the early melanosome targets. 
Aberrant MART1 trafficking would likely affect PMEL function, inhibiting the efficient structure 
formation and subsequent melanin production within melanosomes. We observed that melanin 
production is largely inhibited but not completely blocked providing evidence for redundant 
pathways. Melanosomes are still able to form, mature, and traffic; however, their ability to 
efficiently and effectively produce melanin is hindered. We propose that in the absence of 
STX17, MART1 is unable to be transported to the melanosomes and aberrantly accumulates in 
the cell. Moreover, due to the antigenic nature of MART1, the melanocyte antigenic load 
increases resulting in inappropriate recognition by auto-reactive CD8+ T cells and subsequent 
autoimmune attack (Figure 22). Although we propose compelling evidence for this model, more 
work is needed to elucidate the precise mechanism of STX17 function in melanocytes. 
This functional approach using targeted sequencing of a GWAS region in a complex 
disease and application of both in silico and experimental assays allowed us to elucidate the 
role of genetic variants in AA disease pathogenesis and can be applied as a model to the 
genetics field as whole. Additionally, the novel role identified for STX17 in melanocyte biology 
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and antigenicity is pertinent to both the autoimmune and oncology fields. The study in 
Lipizzaner horses that identified the causal STX17 4.6kb-duplication in premature graying, 
additionally found that gray horses with the duplication had higher incidence of melanomas. The 
melanomas from the gray horses exhibited increased expression of both STX17 and 
neighboring gene, NR4A373. Our data suggested that in the absence of STX17, melanocytes 
accumulate antigens that result in aberrant autoimmune attack. Conversely, perhaps increased 
levels of STX17 leads to an immune evasion phenotype and subsequent melanoma 
development. Therefore, STX17 could be an important target for not only treating melanocyte-
related autoimmune diseases, such as AA, but also melanomas.  
Through the use of a multi-dimensional functional genomics approach, we successfully 
identified candidate causal variants in the STX17 region that were responsible for driving the 
GWAS association and proposed a potential mechanism explaining the elusive preferential 




Figure 13 | Flowchart of variant identification strategy in STX17 risk region. Targeted sequencing was
performed on 849 AA individuals in the 550 kb GWAS association region spanning the STX17 LD block and
identified 5841 variants present in AA cases. 4037 AA variants fell in a loosely linked region defined as r2≥0.4. 693
AA variants were identified in region of tight linkage, defined by r2≥0.8 35 of the variants were in high LD with
GWAS tagSNP, rs107060706, with an individual r2 ≥	0.8. Variant-level significance was calculated for all variants
in the region spanning the high LD region (64.5 kb, chr9:102669557-102734130) using gnomAD Non-Finnish
European (nfe) control allele counts and Fisher’s exact test. P-value threshold was adjusted for number of tests
performed (n=465). 33 of the 35 variants on the risk haplotype were significantly associated with AA (p>0.000108).
32 of the significant AA variants were identified as eQTLs in the scalp skin of AA cases (using a pairwise t-test). In
silico algorithms (FUN-LDA) and Roadmap epigenetic annotations predicted 3 variants to likely be driving the
regulatory effects of the haplotype.
5841
Total variants
5841 variants called in 550kb sequenced region in AA cohort
4037
Linked Region
4037 AA variants within chr9:102669557-103053538 of r2≥0.4 using LDproxy
693
High LD region
693 AA variants within chr9:102669557-102734130 r2≥0.8 using LDproxy
35
Risk Haplotype
35 AA variants in high LD (r2 > 0.8) with tagSNP rs10760706
33
Significantly associated with AA
33 risk haplotype variants are significantly associated with AA after correction for multiple tests (α=0.05/465=1.08E-04)
[465 variants with gnomAD QC allele counts in the high LD region that the risk haplotype spans chr9:102669557-102734130]
32
Genotype-dependent effect on skin expression
eQTL analysis using multi-dimensional datasets on 41 AA patients identified 32 significantly associated variants 
on the risk haplotype that effect gene expression in the skin 
3
In silico predicted effects








Figure 15 | 35 risk variants define the AA risk haplotype. a, Plot of 550 kb region spanning STX17 GWAS
association region. STX17 GWAS variants in green; rs10760706 associated with AA, rs9556 associated with hair
color heritability. Horse duplication associated with premature hair graying (in red) resides in same 3’ STX17 gene
end as the GWAS variants. r2 plot (black peaks) depicts r2 value of variants in relation to rs10760706. Yellow ticks
denote location of variants with r2 ≥ 0.4 or 0.8, respectively. Dark blue, light blue, and turquoise tracks denotes the
location of AA variants in the whole region, in the loosely linked region(r2 ≥ 0.4), and in the tight LD region (r2 ≥
0.8), respectively. 35 variants (green-blue ticks) were in high LD (r2 > 0.8) with rs10760706 and define the risk
haplotype driving association at this locus. b, 465 variants in the LD block with gnomAD data available. GWAS
SNP in blue. 35 variants in high LD (red). 33 are significantly associated with AA (-log10 p-value). Dotted line
signifies p-value threshold. + represent 35 variants on risk haplotype.





















































































































































Table 1 | 35 AA risk variants identified as skin eQTLs. Table of 35 variants that define the risk haplotype. Risk
alleles are in red. AA and control (ctrl) minor allele frequencies (MAF) are listed with r2 values relative to GWAS SNP,
rs10760706 (red underlined). Association (Assoc) p-value is the FET p-value comparing the distribution of AA allele
counts compared to gnomAD non-Finnish European (nfe) allele counts. GTEx column lists p-values ascertained from
GTEX eQTL data of individual variant’s effect of STX17 expression in suprapubic skin (not sun exposed). AA eQTL p-
value is the statistical significance measured by pairwise t-test with FDR correction of the genotype-dependent effect of
variant risk alleles on the expression of STX17 in the scalp skin of 41 AA patients. * denotes the SNP identified to be













rs2416935 G T 'STX17' 36.26% 30.62% 1 2.9E-06 1.1E-30 0.044
rs7039716 A T 'STX17' 36.26% 30.64% 1 2.92E-06 1.1E-30 0.044
rs7027813 A G 'RP11-60I3.4' 36.29% 30.56% 1 1.86E-06 3.9E-31 0.044
rs2416936 A T 'RP11-60I3.4' 36.35% 30.60% 1 1.87E-06 3.9E-31 0.044
rs4742777 T C 'STX17' 36.32% 30.59% 1 1.92E-06 2.8E-31 0.044
rs2416937 A C 'STX17' 36.49% 30.64% 1 1.22E-06 2.8E-31 0.044
rs4743370 G T 'STX17' 36.30% 30.64% 1 2.51E-06 2.8E-31 0.044
rs10760700 A G 'STX17' 36.25% 30.62% 1 2.88E-06 1.1E-30 0.044
rs2900224 C T 'STX17' 36.24% 30.78% 1 6.23E-06 2.8E-31 0.044
rs10121880 A G 'STX17' 36.30% 30.58% 1 1.9E-06 2.8E-31 0.044
rs10121601 G T 'STX17' 36.30% 30.70% 1 3.31E-06 2.8E-31 0.044
rs10124366 A G 'STX17' 29.67% 25.55% 0.86 0.000318 8.3E-25 0.12
rs10117828 G A 'STX17' 36.45% 30.55% 1 9.17E-07 2.8E-31 0.044
rs4282626 A G 'STX17' 36.30% 30.59% 1 2.08E-06 2.8E-31 0.044
rs11387575 AT A 'STX17' 36.43% 30.64% 1 1.6E-06 2.8E-31 0.044
rs9299335 A G 'STX17' 36.37% 30.50% 1 1.18E-06 2.8E-31 0.044
rs2416940 T C 'STX17' 36.35% 30.60% 1 1.88E-06 2.8E-31 0.044
rs7022999 C T 'STX17' 36.39% 30.72% 1 2.49E-06 2.8E-31 0.032
rs5899398 T TG 'STX17' 36.20% 31.17% 1 0.000034 1.1E-30 0.044
rs4742778 G T 'STX17' 36.29% 30.67% 0.98 2.88E-06 2.8E-31 0.044
rs2416942 C G 'STX17' 36.45% 30.61% 1 1.23E-06 2.8E-31 0.044
rs10760704 A G 'STX17' 36.27% 30.59% 1 2.43E-06 1.1E-30 0.048
rs7038506 C T 'STX17' 36.19% 30.63% 1 3.75E-06 1.1E-30 0.044
rs10217337 A G 'STX17' 36.37% 30.60% 1 1.59E-06 2.8E-31 0.044
rs10217692 T C 'STX17' 36.39% 30.66% 1 1.88E-06 2.8E-31 0.044
rs10217366 T G 'STX17' 36.49% 30.56% 1 9.03E-07 2.8E-31 0.044
rs2031035 G A 'STX17' 36.15% 30.62% 1 4.55E-06 2.8E-31 0.048
rs1852863 G A 'STX17' 35.89% 30.54% 1 9.68E-06 1.1E-30 0.044
rs1997367 G A 'STX17' 36.04% 30.55% 1 5.35E-06 3.1E-30 0.044
rs7027619 G T 'STX17' 36.13% 30.62% 1 4.87E-06 2.8E-31 0.044
rs10760706 T C 'STX17' 36.08% 30.56% 1 4.28E-06 1.3E-30 0.044
rs66799478 T TACA 'STX17' 36.30% 30.86% 1 6.6E-06 2.7E-31 0.044
rs10116142 C G 'STX17' 40.13% 35.82% 0.83 0.000522 2.3E-15 0.02
rs9556* C T 'STX17' 36.30% 30.72% 0.98 3.37E-06 4.9E-30 0.078










Figure 17 | In silico analysis predicts 3 regulatory variants in STX17 and implicates melanocytes as the
disease-relevant cell type. a, FUN-LDA algorithm generated prediction scores (0-1, displayed as peaks) of tissue-
specific regulatory effects for each genomic position spanning STX17 (genomic position, x-axis) in 8 skin cell types.
SNPs denoted as black vertical line. rs7039716 predicted as functional in skin cell types (falls within peaks across all
8 cell types). rs10760706 and rs9556 GWAS SNPs do not fall in predicted regulatory regions. Melanocytes (Mel03)
show additional predicted regulatory regions (blue peaks) in STX17, not seen in keratinocytes or fibroblasts. b, Plot
of Roadmap chromatin state data in fibroblasts (Fib), keratinocytes (Ker), and melanocytes (Mel) across the variant-
defined risk haplotype. 35 AA-associated variants displayed as green ticks. Red represents transcription start sites
(TSS) and yellow represents enhancers. Increase frequency of enhancer regions across the risk haplotype in
melanocyte cells, specifically. Two variants (rs24169356 and rs7039716) fell in TSS across cell types and 1 variant
(rs7027813) fell within a melanocyte-specific enhancer. c, Zoomed in image of region spanning intron 1 and exon 2
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Pathway Enrichment of differentially expressed genes in AA skin
Figure 18 | DAVID Pathway analysis identifies melanogenesis pathway disrupted in AA skin. DAVID
pathway analysis provided functional annotation of affected pathways based on differentially expressed genes
from microarray expression data in the scalp of AA patients compared to controls. Melanogenesis is the 25th most













Figure 19 | STX17 localized to aberrant melanocytes in AA. Immunofluorescent
staining of STX17 (green) and premelanosome protein (PMEL) to mark melanocytes
in hair follicles of a, Healthy Control b, non-lesional biopsy of an Alopecia Areata
Patchy (AAP) patient and c, lesional biopsy of same AAP patient. White box inset
denotes zoomed in area of dysmorphic melanocytes at 40x magnification; white
arrowheads denote detached, dysmorphic melanocytes; DP = dermal papilla. Strong
STX17 staining of the control basement membrane (white dotted line) is lost with
disease progression. In both lesional and non-lesional biopsies we see lack of strong
















































































































































































Figure 20 | STX17 has a novel autophagy-independent role in melanocyte function and antigen accumulation.
a, Decreased melanin production in primary human melanocytes treated with STX17 siRNA. Melanin normalized to
lysate protein levels (μg melanin/mg protein). Visual representation of μg melanin shown in top box. b, Melanin
production increased in melanocytes treated with autophagy inhibitors 3-methyladenine (3-MA, 1 mM for 24hrs),
chloroquine (CQ, 50 μM for 24hrs), and bafilomycinA1 (BA1, 10nM for 24hrs) compared to baseline. c, Electron
microscopy (EM) of human melanocytes at baseline and after STX17 depletion reveal no striking differences in
morphology and melanosome number/localization; 10,000x mag. d, In control and STX17 knockdown conditions,
melanosomes were staged based on the amount of melanin and melanosome morphology. Quantification was
performed blinded to conditions and determined by number of melanosomes per in2 of cellular area. We observed a
significant decrease in early melanosomes in the STX17 KD condition. However, late and total number of
melanosomes are unchanged between conditions. P-value was determined by Welch’s t-test (*=0.03) e, EM of BA1-
treated melanocytes showed accumulation of autophagosomes and multi-vesicular bodies. f, Accumulation of
established AA antigen MART1, an early melanosome protein in STX17-depleted melanocytes. TYR levels are
unaffected. g, After autophagy inhibition with BA1 and 3-MA, TYR and MART1 levels are unchanged. g, CD8+ T cell
infiltrate (arrows) in HFs of two AA patients (one AAP and one AT/AU) with low STX17 skin levels. The median level of





Fig. 21 | STX17 colocalizes with MART1 peri-nuclearly. a, Immunofluorescent staining of primary human
melanocytes for MART1 (red) and STX17 (green) at baseline and b, after 1 μM αMSH treatment for 24hrs to
stimulate melanogenesis. Arrowheads denote the co-localization of MART1 and STX17 in the perinuclear
region. The percentage of co-localization (Co) was calculated in FIJI and represents the percentage of total












Figure 23 | STX17 Mechanism in melanogenesis. Our data suggest a role for STX17 in trafficking of early protein
MART1 to target melanosome organelles. In AA patients with the identified risk haplotype, variants inhibit transcription
resulting in decreased STX17 levels. Reduced levels of STX17 result in inefficient MART1 enzyme transportation,
consequentially hindering melanin production in melanosomes. MART1 antigens unable to properly traffic to the
melanosomes accumulate in the cell and are aberrantly recognized by auto-reactive T cells, eliciting a T-cell response





Figure 22 | STX17 mechanism in melanog nesis. Our data suggest a r le for STX17 in trafficking of early 
protein MART1 to target melanosome organelles. In AA patients with the dentified risk h plotype, variants inhibit 
transcription resulting in decreas d STX17 levels. Reduced levels of STX17 result in inefficient MART1 enzyme 
transportation, consequentially hindering melanin pr duction in melanosomes. MART1 antigens unable o 
properly traffic to the m la osom s accumulat  in the cell a d are aberrantly recognized by auto-reactive T cell , 











Chapter 3 Whole exome sequencing in alopecia areata 
identified mutations in KRT82  





 Alopecia areata (AA) is one of the most prevalent autoimmune diseases and is 
characterized by T-cell mediated immune attack of the hair follicle (HF) resulting in hair loss55. 
As a complex disease, both environmental and genetic factors contribute to AA risk55,65,66. Our 
genome-wide association study (GWAS) and meta-analysis identified common variation in 14 
genetic risk loci, supporting the role for common variants in this complex disease.  We 
previously performed linkage analysis in a cohort of families and found evidence for rare co-
segregating mutations34,  however, the regions we identified were large and precluded the 
identification of causal genes.  Thus, rare genetic variants with strong effect sizes remain 
uncharacterized in AA.  
 Whole exome sequencing (WES) and exome-wide association studies in large cohorts 
of patients with complex disorders such as congenital kidney malformations119, amyotrophic 
lateral sclerosis6, pulmonary fibrosis7, epilepsy8, coronary disease9, myocardial infarction10, and 
autism11 have successfully identified rare disease variants using WES followed by gene-level 
collapsing approaches. As variant allele frequencies decrease, the power to detect associations 
simultaneously decreases due to the lack of observations to inform statistical analyses44. As a 
result, variant-level analysis in WES is limited by the need for large sample sizes to achieve 
power133. Therefore, gene-level collapsing methods have emerged as the accepted framework 
for identifying enrichment of variants in a given gene, or genetic burden, in disease cases 
compared to controls119. Model parameters, such as variant function and population frequency, 
are then used to select qualifying variants for testing. The frequency of qualifying variants within 
a gene is compared between cases and controls, and statistical significance is established to 
determine whether a gene has increased mutational burden in cases. 
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 We performed WES and gene-based collapsing in 849 AA cases and 15,640 controls to 
assess the genetic burden of rare damaging mutations in unknown genes associated with AA.  
 
3.2 KRT82 identified as an AA risk gene 
In the first rare variant collapsing model, we performed a gene-based analysis by 
evaluating only rare, loss of function (LOF) variants with a minor allele frequency (MAF) ≤1% in 
the general population (gnomAD populations) and our sequencing cohorts (cases and internal 
controls)121. Stringent quality control (QC) metrics were further imposed on the variants. Using 
this approach across 18,653 protein-coding genes, we identified Keratin 82 (KRT82) as the only 
genome-wide significant (at a significance level 0.05/18,653 = 2.68x10E-06) AA case-enriched 
gene (OR=4.04, p=2.03×10E−06), with variants detected in 19 out of 849 cases (2.24%) 
compared to 88 out of 15,640 controls (0.56%) (Figure 23a,d). KRT82 is predicted to be tolerant 
to protein truncating variants due to the observed frequency of LOF variants in the general 
population (gnomAD, pLI=0; o/e=1.12)121. The tolerant nature of KRT82 prompted us to perform 
an additional analysis of common LOF variants to ensure that rare KRT82 LOF variants were 
truly enriched in our AA population, and not an artifact of genic tolerance and exclusion of 
common variants. The common (MAF >1%) LOF analysis did not identify additional mutations in 
KRT82, indicating that the rare model did not exclude any relevant common variants that would 
have dampened the significant enrichment of KRT82 LOF mutations in our AA population. The 
rare LOF model also identified another hair keratin-related protein, KRTCAP3 (Keratinocyte 
Associated Protein 3) as the second most significant AA association (p=1.28E-04) with rare 
LOF qualifying variants in 9/849 (1.1%) AA cases and 30/15,640 (0.19%) controls (Figure 23d). 
However, testing in a larger cohort may be needed to achieve a genome-wide significant 
association with AA. 
Next, the second model expanded upon the previous model to include rare variants 
(MAF ≤1%) that were non-synonymous coding (missense) or canonical splice variants and 
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predicted to be possibly or probably damaging by PolyPhen‐2 HumVar134. The inclusion of 
damaging missense variants strengthened the evidence for KRT82 association 
(p=9.19×10E−07, Figure 23b, d), and identified qualifying variants in 47 out of 849 cases 
(5.54%) compared to 376 out of 15,640 controls (2.4%; OR=2.38). This indicated that the 
KRT82 association with AA was evident both when protein expression was decreased due to 
protein truncating variants (LOF model), as well as when protein structure was altered by a 
missense variant (LOF + missense model).  
We postulated that if KRT82 was enriched for both LOF and damaging missense 
variants, a stronger signal would be observed with the inclusion of qualifying synonymous and 
splice region variants predicted to be pathogenic. We used the Transcript-inferred Pathogenicity 
score (TraP-score, version 2.0)18, which predicts whether a synonymous or intronic variant can 
damage the mRNA transcript by disrupting the splicing process, resulting in perturbed protein 
formation and subsequent disease risk135-137. We constructed an additional splicing model 
(Figure 23c-d) that expanded on the previous LOF and missense models to also include 
predicted pathogenic splice variants and non-synonymous variants with a TraP-score ≥ 0.2, 
which is above the 90th percentile of pathogenic scores and considered possibly damaging 
(http://trap-score.org/about.jsp). Notably, this model also identified KRT82 as harboring the most 
significantly enriched variants in AA cases, achieving a stronger enrichment of p=2.2×10E−07, 
OR= 2.41 (Figure 23c-d) and surpassing genome-wide and study-wide thresholds for 
significance (α=2.68E−06 and 3.83E−07 respectively). The increased significance was due to 
an additional splice region variant (Arg314Gln) that had a high TraP-score (0.55) prediction as 
protein-damaging and was found in four additional cases. As a result, this splicing model 
identified a total of 51 of 849 AA patients (6.01%) with rare damaging variants in KRT82, 
compared to 404 out of 15,640 controls (2.58%).  
We found that the genomic inflation factor (λ), which measures potential false-positive 
associations, varied across these models in a manner that is consistent with the mutation type 
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that is included in each model. For example, LOF variants have a higher probability of exerting a 
phenotypic effect than other mutation types138,139.  Accordingly, we observed the lowest estimate 
of genomic inflation for the LOF model (λ=1.03) (Figure 23a). We found greater estimates for 
the LOF + missense analysis (λ=1.18) and the splicing analysis (λ=1.23), models for which we 
expected a potentially higher proportion of clinically benign qualified variants (Figure 23c). To 
investigate further, we tested an additional model as a negative control, using rare synonymous 
variants as qualifying criteria (MAF ≤ 0.01%). As expected, we did not observe any genes with 
significant enrichment. The genomic inflation factor (λ) for this model was 0.91 (Figure 24). 
Taken together, the overall low inflation of the cohort in the synonymous analysis represented 
the null distribution and absence of global inflation due to genotyping discrepancies or 
population stratification. It provided further confidence for a true association between rare, 
damaging KRT82 mutations and AA. 
 Qualifying variants in these gene-collapsing models included predicted damaging 
mutations such as stop-gained (nonsense), frameshift, splice site, and nonsynonymous 
damaging amino acid substitutions (missense) (Table 2).  Eleven protein-altering variants (3 
nonsense, 7 damaging missense, 1 splicing) accounted for the variation detected in 51 of our 
AA cases (Table 2). One KRT82 mutation with the highest frequency in our AA cohort was 
found in 15 cases (1.77%) and resulted in a nonsense mutation at amino acid position 47 
(R47X). Furthermore, 7 out of the 11 variants were shared among more than one individual. The 
pathogenicity of these individual variants was supported by their recurrent nature and increased 
frequency in our disease cohort, even though the mutations were rare (MAF ≤ 1%) in the 
general population. However, none of the individual variants could exceed the genome-wide 
significance threshold on their own, underscoring the necessity of gene-level analysis in 




3.3 AA KRT82 variants annotated as likely disease-causing 
 The identification of KRT82 as an AA risk gene emphasized the utility of WES in 
uncovering functionally relevant disease loci in complex diseases. KRT82 encodes a type II 
hair-specific keratin with exclusive expression in the cuticle of the hair shaft140-142. Keratins are 
intermediate filaments (IF) that provide a cellular structural network via the heterodimerization of 
type I with type II keratins in epithelial cells89. The keratin family of proteins are composed of 
well-defined evolutionarily conserved domains consisting of a head domain, a 310-amino acid 
α-helical rod domain, and a tail domain143. The rod domain is necessary for forming the coiled-
coil α-helical dimer between type I and II keratins, and is made up of 4 subdomains, 1A, 1B, 2A, 
2B143,144. Additionally, the keratin II head domain is crucial for tetramer stabilization and IF 
assembly145. Variants that disrupt the 1A, 2B, or type II head and tail domains in keratins have 
been reported as pathogenic in various other diseases, underscoring the importance of these 
domains in proper keratin function110,143.  
We identified 11 rare, damaging variants in 51 patients that contributed to the KRT82 
association with AA (Table 2). Strikingly, 9 out of the 11 KRT82 variants fell within one of the 
keratin disease-associated subdomains, consistent with the predicted damaging effect of these 
variants (Figure 25a-b). Three KRT82 variants resided in the head domain (Ser16fs, Arg47X, 
Ile92Val), one in coil 1A (Asn129Lys), three in coil 2B (Arg314Gln, Arg314Trp, Glu351Lys), and 
two in the tail domain (Gly436Arg, Gly436Trp) of KRT82 (Figure 25a-b). Since these regions are 
essential for keratin function and dimerization, we postulated that the KRT82 AA risk variants 
likely disrupt KRT82 function and dimerization with its respective potential binding partners 
(KRT32, KRT35, KRT39, or KRT40), consequentially destabilizing the hair shaft cuticle. 
Therefore, damaging variants in these well-defined disease-associated regions have the 




Additionally, all identified damaging variants fell within evolutionarily conserved residues 
across distantly related species, further supporting the importance of these amino acids in 
KRT82 biology (Figure 25c). Highly conserved genes are often considered intolerant to 
mutations and undergo negative purifying selection against deleterious alleles146. Since 
important functional residues are often evolutionarily conserved across species, variants 
occurring at these positions are more likely to be pathogenic146-148. The enrichment of KRT82 
variants in established functional disease domains and evolutionarily conserved amino acids 
supported a damaging effect of these variants on KRT82 function.  
  
3.4 KRT82 variants associated with AA pathology 
Within the large family of epithelial keratins, hair keratins (type I and type II) are a 
subfamily responsible for the “hard” keratinization of hair and nails89,140. Interestingly, mutations 
in type II hair keratins (KRT81-86), but not type I (KRT31-40), have reported associations with 
other genetic hair disorders such as Monilethrix, pseudofolliculitis barbae, and hair ectodermal 
dysplasia 108,110,142. Specifically, mutations in the 1A and 2B domains of KRT81, KRT83, and 
KRT86 resulted in Monilethrix, a rare monogenic hair loss disorder (Figure 25a)108,143. The 
causal role of type II hair keratins in genetic hair loss diseases validated their important role in 
healthy hair structure and further strengthened the functional association between AA and 
KRT82, a type II hair keratin. Due to the known roles of other type II hair keratin genes in other 
monogenic hair loss disorders, we next confirmed that our patients were accurately diagnosed 
with AA, and not a monogenic hair loss disorder misdiagnosed as AA in our cohort. We 
confirmed accurate AA diagnoses through clinical validation, biopsy immunohistochemistry 
(IHC), and inflammatory ALADIN gene expression signatures (Figure 26a-c). In four AA patients 
with a KRT82 missense mutation, IHC of scalp samples revealed interfollicular infiltrate of CD8+ 
lymphocytes, a diagnostic feature of AA (Figure 26b). The ALADIN (Alopecia Areata Disease 
Severity Index) index utilizes expression profiles of keratin and inflammatory gene signatures to 
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distinguish AA scalp from control124. Gene expression data from three patients with a KRT82 
mutation confirmed an increased inflammatory ALADIN signature, with the patients clustering in 
the AA cohort and away from controls (Figure 26c). Using these three methods, we were 
confident that the patient’s diagnosis of AA was accurate, and not a form of a monogenic hair 
loss disorder.  
 
3.5 AA susceptibility was specific to KRT82 variation 
 Due to close chromosomal localization and structural similarities in the keratin gene 
family, we tested whether the observed increased variation in KRT82 was due to 
hypermutability in the chromosomal region or keratin family of genes. We applied the same 
model parameters to specifically investigate variant frequencies in 7 other keratin genes (KRT5, 
KRT84, KRT85, KRT32, KRT35, KRT39, KRT40) located both proximally and distally to KRT82 
(Figure 27a-b). KRT84 and 85 are type II hair keratins located 8.3 kb and 26.4 kb upstream of 
KRT82, respectively. KRT5 is a type II epithelial keratin that is located on chromosome 12, 
120.6 kb away149. KRT32, KRT35, KRT39, KRT40 are all type I hair keratins and proposed 
binding partners of KRT82 due to their reported co-expression patterns in the HF cuticle89. Each 
of these keratin genes harbored markedly less variation than KRT82. For example, only 1 AA 
patient carried a LOF mutation (KRT85) out of the 7 of the additional keratin genes queried, 
whereas 19 AA cases harbored a KRT82 LOF mutation (Figure 27b). Furthermore, none of the 
additional keratin genes that we investigated carried a significantly higher genetic burden of rare 
variants in cases compared to controls. The lack of significant AA-associated variation in any of 
the putative binding partners of KRT82 or keratin family members suggested a specific role for 
KRT82 in the genetic pathomechanism in AA. Additionally, these results confirmed that the AA-
associated risk is driven specifically by KRT82 variation and was not a result of broad 




3.6 Haplotype analysis identified a hotspot mutation R47X in KRT82 
 We next asked whether the KRT82 mutation R47X was a “hotspot” versus a founder 
mutation that was dispersed across the population. Some regions of the genome are “hotspots” 
that have a propensity to spontaneously give rise to de novo mutations, increasing the 
frequency of disease mutations in the population. For example, another dermatologic disorder, 
epidermolysis bullosa simplex (EBS), is associated with hotspot mutations in keratin genes 
KRT5 and KRT14 that result in ineffective cross-linking and bundle formation150-152. For a 
hotspot mutation, the same mutation will be carried on multiple different haplotypes, whereas a 
founder mutation will be found on one common haplotype, suggesting the presence of a 
common ancestor. To distinguish these possibilities, we analytically phased our sequence data 
to identify haplotypes carrying KRT82 mutations153. We found that the most frequently occurring 
nonsense mutation, R47X was present on at least 6 different haplotypes, indicative of a hotspot 
mutation (Figure 28, Table 3).  
Disease-associated mutational hotspots commonly occur at CpG dinucleotides that 
result in spontaneous deamination of 5-methylcytosine in C > T transitions154-158. Interestingly, 
the R47X mutation in KRT82 resulted from a C > T transition at a methylated CpG residue 
(Figure 28b). In this context the 5’-CGA-3’ encoded an arginine (Arg; R) that resulted in a 
nonsense mutation when 5’-methylcytosine was deaminated to thymine (T). As a result, R47X, 
the most frequent KRT82 mutation in AA patients (15/849; 1.77%), is predicted to be a hotspot 
mutation arising from a spontaneous deamination at a methylated CpG site.  
  
3.7 KRT82 is exclusively expressed in anagen phase 
 Previous studies reported the expression of KRT82 in the hair shaft cuticle of both 
human and sheep hair follicles and identified it as a hair-specific type II keratin140-142. However, 
its functional role in hair follicle biology has yet to be elucidated. Cell culture studies 
investigating the role of KRT82 are challenging due to its differentiated nature as a hair follicle 
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keratin. Therefore, we focused functional analyses on in vivo mouse models, to characterize the 
spatiotemporal expression of KRT82 throughout the murine hair follicle cycle, which consists of 
the three stages including anagen (growth), catagen (regression), and telogen (quiescence).  
We found that KRT82 was expressed in the hair follicle cuticle exclusively during the growth 
stage of anagen (Figure 29) and was absent in catagen and telogen. Thus, KRT82 expression 
in the anagen HF is biologically relevant in the context of AA, since the autoimmune attack is 
known to occur exclusively during anagen, resulting in the premature entry of the HF into 
catagen.  
  
3.8 Reduced expression of KRT82 in AA patients 
 We next investigated the expression of KRT82 in control human hair follicles using 
immunofluorescence (IF) staining and found strong expression of KRT82 in the anagen hair 
shaft cuticle, as previously reported (Figure 30a). In control HFs, KRT82 cuticle expression 
began in the bulb, just above the Line of Auber, and extended up the HF towards the epidermis. 
We found specific subcellular KRT82 localization in the cytoplasm of the hair shaft cuticle cells, 
consistent with the role of keratins as cytoskeletal intermediate filaments (IF)143. We compared 
KRT82 expression in control versus AA patient HFs and found markedly decreased expression 
of KRT82 in AA hair shaft cuticles (Figure 30a). In contrast to control HF, KRT82 expression in 
AA follicles was absent in the cuticle including the bulb, the site of AA immune attack. This 
finding is noteworthy in the context of AA disease onset due to the characteristic immune 
infiltrate surrounding the follicular bulb, where we identified loss of functional KRT82 expression 
in AA HF.  
 In support of this observation, our previous gene expression studies reported a 
significant -4.5 log-fold decrease in expression of KRT82 in the scalp skin of AA patients 
compared to controls (Benjamini-Hochberg-corrected p=3.55E-10)124. We found that not only 
was KRT82 expression significantly decreased in AA patients relative to controls, but KRT82 
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downregulation was also significantly correlated with disease severity (Figure 30b). Biopsies 
taken from nonlesional (hair-bearing) sites of AA Patchy (AAP) scalps revealed a slight 
reduction in KRT82 expression compared to controls (p=0.028) (Figure 30b). In lesional sites of 
hair loss in AAP patients and patients with total loss of scalp and body hair (AT/AU; alopecia 
areata totalis/universalis), KRT82 was significantly decreased compared to healthy controls 
(p<0.0001) (Figure 30b). The insignificant change in KRT82 levels in AAP nonlesional 
compared to lesional biopsy sites (p=0.068) suggested that decreased expression observed in 
patients was not simply a result of loss of the KRT82-bearing HF, but rather a predisposed 
reduction in functional KRT82 expression that strongly correlated with active disease sites and 
disease severity (Figure 30b). However, it cannot be ruled out that significant differences 
between nonlesional and lesional samples may be observed with a larger sample size. Our 
results suggested that decreased functional KRT82 in the hair cuticle may predispose 
genetically susceptible individuals to AA-mediated hair loss.  
To further investigate the role of the identified rare, damaging variants on skin tissue 
expression of KRT82, we tested whether individuals with qualifying KRT82 variants 
demonstrated altered KRT82 levels in the scalp skin independent of the presence of hair 
follicles (i.e. nonlesional & lesional biopsies) in 20 AAP individuals.  Patients with a confirmed 
damaging mutation in KRT82 trended towards lower expression levels of KRT82, independent 
of biopsy type (Figure 30c), although the difference was not statistically significant due to the 
small sample size of patients with a damaging variant and expression data. This suggested that 
the identified damaging mutations functionally altered/truncated KRT82 protein structure, 
resulting in decreased functional expression in the skin of AA patients.  
We next characterized the functional effect of KRT82 variants in the HF by assessing 
KRT82 and CD8 expression in lesional scalp biopsies of 3 patients with one of the damaging 
KRT82 mutations. Lesional biopsies from two of the patients with a missense KRT82 mutation 
(Asn129Lys, Gly436Trp) revealed reduced or absent expression of KRT82 in the HF cuticle 
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(Figure 30d). Both patients also had increased CD8+ T cell follicular infiltrate compared to 
control HFs. In the third patient with a missense KRT82 mutation (Arg302His), we observed HFs 
with cuticular KRT82 expression intact, however, with less severe perifollicular CD8+ T cell 
infiltrate (Figure 30d) compared to the patients with absent KRT82. These findings suggested a 
model in which rare damaging mutations in KRT82 resulted in reduced protein function or 
expression, predisposing AA patients to compromised HF cuticles, and rendering the HF 
vulnerable to autoimmune attack, supported by the observed negative correlation between 
perifollicular CD8+ T cell infiltrate and KRT82 HF cuticle expression.  
  
3.9 Discussion 
 This study presents the first large-scale WES of AA patients and identification of novel 
rare variants contributing to disease risk. Our analysis approach utilized a gene-level collapsing 
approach to identify a type II hair keratin gene, KRT82, as the only gene harboring significantly 
more rare damaging variants in AA cases (6.01%) compared to controls (2.58%) (p=2.18E-07), 
achieving both genome-wide and study-wide significance. The predicted damaging effects of 
the variants were supported by their localization to evolutionary conserved residues and known 
disease-causing keratin domains.  
In order to define the underlying mechanism for the association between KRT82 and AA, 
we interrogated the role of KRT82 in hair follicle biology. We observed that KRT82 is expressed 
in the hair shaft cuticle exclusively in the growth phase of anagen, when AA-directed immune 
attack occurs. During disease, anagen-directed inflammatory infiltrate prematurely propels the 
anagen HF into catagen. The absence of KRT82 in AA hair shaft cuticles may cause HF 
dysfunction and subsequent premature entry into catagen, as seen in disease. In support of 
this, hair follicles in KRT17-null mice exhibit hair shaft fragility, aberrant apoptosis, and 
premature entry into catagen159. In the absence of KRT17, keratinocytes are more susceptible 
to TNFα-mediated apoptosis and HFs prematurely undergo the anagen-catagen transition, 
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demonstrating a critical role of a single keratin, KRT17, in hair cycle regulation and suggesting a 
plausible role for other keratins, such as KRT82 in regulation of apoptosis and HF cycling. 
Further support for the role of KRT82 in hair loss is seen in the Sox21 knockout (Sox21-/) mouse 
model of cyclic alopecia that demonstrated altered keratin expression signatures, including a 
prominent reduction of KTR82 in the hair shaft cuticle141. The resulting phenotype led to hair 
loss during late first telogen and catagen stages. Although other keratin levels were affected in 
this animal model, the decrease in KRT82 and association with cyclical alopecia substantiates 
an important role for KRT82 in hair follicle biology, underscoring the role for LOF and damaging 
variants in AA pathogenesis.  
Further functional annotation of KRT82 revealed that its expression was largely reduced 
in the scalp skin biopsies and HFs of AA patients. All 51 AA patients in which mutations were 
detected are heterozygous carriers of damaging risk variants, which correlated with lower levels 
of KRT82 expression supporting a haploinsufficiency model. The absence or reduced 
expression of KRT82 in the HF, in addition to increased perifollicular CD8+ T cells support an 
important relationship between KRT82 function and the organ-specific AA-mediated immune 
attack. We postulate that hair shaft cuticle formation is dependent on KRT82 and absence of 
normal expression renders the bulb vulnerable to infiltration of auto-reactive immune cells.  
As the outermost layer of the hair shaft, the hair cuticle protects the internal layers of the 
HF against mechanical and environmental insults through a high content of crosslinking 
between type I and type II keratins160. It also plays a crucial role in anchoring the growing hair 
shaft to the inner root sheath (IRS) during anagen160. Disrupted and absent cuticles are seen in 
exclamation mark hairs (EMH), a characteristic diagnostic feature of AA56. Previous reports 
demonstrated that absent cuticles in AA EMHs revealed areas of high shaft disorganization56. 
Additionally, some hairs revealed structural cuticle deformities with a high density of vacuoles56. 
The authors suggested that the cuticle disruption negatively impacts AA HF integrity, causing 
vulnerability to mechanical insults56. Our findings of a genetic association between damaging 
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KRT82 variants with AA and the literature reports of aberrant cuticles in AA EMHs supports a 
critical role for the hair shaft cuticle in AA pathogenesis. Additionally, we found that KRT82 
mutations were predicted to perturb the protein product, potentially resulting in disorganized or 
absent hair shaft cuticle structures.  
Although the target antigens in AA have not been conclusively identified, keratins are 
attractive candidate auto-antigens due to their abundant expression in the HF. Auto-antibodies 
against anagen keratinocytes in the cuticle, matrix, and cortex were previously identified in a 
subset of autoimmune polyendocrine syndrome type 1 patients with alopecia areata totalis 
(AT)161. Human and mouse AA auto-antibody reactivity was also reported against anagen HF-
specific antigens ranging from 40-60 kDa, specifically 44/46 kDa keratins95,161,162. Type I keratins 
are 44-48 kDa and dimerize with type II keratins (55-60 kDa) to form IF bundles and structural 
networks in cells89,140. In AA, absence of the type II keratin, KRT82 in the cuticle would leave its 
type I binding partner (KRT32, KRT35, KRT39, or KRT40) unable to heterodimerize. We 
postulate that without functional KRT82, unbound type I binding partners could be aberrantly 
presented as autoantigens. However, further work on the potential AA keratin auto- antigens 
remains to be done.  
 Here, we used WES and gene-level mutation analyses to identify a functionally relevant 
disease gene, KRT82. We identified eleven rare damaging variants, including the most frequent, 
R47X, a mutational hotspot, and characterized negative consequences on KRT82 expression 
and function in AA. Our work uncovered a novel mechanism involving genetic susceptibility for 
disrupted cuticle structures rendering susceptibility to AA. This work not only elucidates a 
previously unknown mechanism of end organ genetic susceptibility in an autoimmune disease 
but also encourages potential new therapeutic approaches for treatment of AA. Treatments 
targeted at restoring HF integrity are advantageous due to the distinct ability of the HF to 
regenerate in AA, since the target organ is damaged, but not destroyed. In summary, we 
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characterized the role of rare variants in AA susceptibility and identified a novel disease 
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Figure 23 | Gene-level collapsing models identify significant rare variation in KRT82. Q-Q
plots of a, Loss of Function (LOF) Model. b, LOF + damaging missense Model. c, LOF +
missense + splicing variants predicted by high TraP scores (≥ 0.2). The genomic inflation factor
(λ) is 1.03, 1.18, 1.23, respectively. The blue line represents the null hypothesis (observed p-
values correspond to expected p-values), the yellow line marks the 2.5th percentile of expected p-
values, and the green line marks the 97.5th percentile of expected p-values. d, Table of three
models that identified rare variants in KRT82 that were enriched in AA cases with genome-wide
significance (p>2.68E-06). Each model lists the top three genes with highest significance (Gene
Column). Table outlines the number and frequencies (Freq) of cases and controls with qualifying








Model Gene Cases Controls Case Freq Ctrl Freq P-value
KRT82 19 88 2.2% 0.56% 2.03E-06
KRTCAP3 9 30 1.1% 0.19% 1.28E-04
DECR2 6 11 0.7% 0.01% 1.39E-04
KRT82 47 376 5.5% 2.4% 9.19E-07
ZNF418 0 271 0% 1.7% 1.04E-06
PCCB 2 321 0.2% 2.1% 1.02E-05
KRT82 51 404 6.0% 2.6% 2.18E-07
NCOA3 4 419 0.4% 2.7% 3.54E-06











Figure 24 | Rare but Synonymous Variant Gene Collapsing Model. Qualifying variants in this
model included any rare (MAF ≤ 0.01%) and synonymous variants, that are predicted to have no
pathogenic role. a, Low inflation (lambda (λ) = 0.91) of representative Q-Q plot. b, No genes
reached genome-wide significance in rare synonymous variant model, serving as a negative
control. Synonymous variants do not affect the protein product, and therefore should not have a
pathogenic effect or be associated with disease. Under this rationale, distribution of p-values
should follow the null distribution without any any significant associations, as seen here.
Model Gene Cases Controls Case Freq Ctrl Freq P-value
AQP2 6 13 7.1% 0.08% 2.79E-04
OTOF 0 151 0.0% 0.97% 6.09E-04








Table 2 | Damaging KRT82 amino acid changes in AA cases. List of the 11
qualifying variants present in AA cases, sub-divided by variant types included in each
of the three models. Each model includes qualifying variants from the previous
model. For example, LOF + missense Model includes the 3 LOF variants in 19
cases, plus 7 missense variants in 28 new cases, for a total of 10 variants in 47
cases. Qualifying variants exclusive to cases (n=50) were not individually listed in
this table but accounted for the total number of controls with a qualifying variant
(Controls column). As an example, 88 controls had a LOF variant in KRT82 but the
Arg47X, Ser27X, and Ser16fs variants account for 78 individuals. 10 controls
harbored qualifying KRT82 LOF variants that were not present in AA cases and
therefore not listed in this table.
Type Cases Controls Case Freq Ctrl Freq P-value
LOF 19 88 2.24% 0.56% 2.03E-06
Arg47X 15 72 1.77% 0.46% 3.42E-05
Ser272X 3 3 0.35% 0.02% 2.42E-03
Ser16fs 1 3 0.12% 0.02% 0.19
LOF + missense 47 376 5.54% 2.40% 9.19E-07
Asn129Lys 14 101 1.65% 0.65% 2.34E-03
Ile92Val 4 46 0.47% 0.29% 0.33
Glu351Lys 4 37 0.47% 0.24% 0.16
Arg314Trp 3 22 0.35% 0.14% 0.14
Arg302His 1 7 0.12% 0.04% 0.34
Gly436Arg 1 2 0.12% 0.01% 0.15
Gly436Trp 1 2 0.12% 0.01% 0.15
LOF + missense + splicing 51 404 6.01% 2.58% 2.18E-07





Figure 25 | KRT82 variants are localized to highly conserved disease-annotated domains.
a, Table of 9 of the KRT82 damaging mutations that fall in a domain previously associated with
pathogenic keratin mutations in other diseases. b, schematic representation of KRT82 with
domains (turquoise), AA variants (blue), and conservation score (purple) (1=highly conserved).
c, Conservation of KRT82 amino acids across 7 different species: human, mouse, sheep,
rhesus monkey, sea lion, vampire bat, and armadillo. AA variants are highlighted in red (LoF),
blue (Missense), and green (Splicing). Amino acid change of variant is annotated in red above.
Abbr: EBS= epidermolysis bullosa simplex; CC= Cryptogenic Cirrhosis; DNEPPK= diffuse non-
epidermolytic palmoplantar keratoderma; BCIE= bullous congenital ichthyosiform erythroderma;
IBS= ichthyosis bullosa of Siemens; MECD= Meesmann’s epithelial corneal dystrophy; WSN=
white sponge nevus; PC=pachyonychia congenita; FNEPPK= focal non-epidermolytic








Disease Domain No. KRT82 AA Variants AA Variant Types Domain-associated Disease References
Type II Head 3 Ser16fs, Arg47x, Ile92Val EBS, DNEPPK Smith et al. (2003)
Coil 1A 1 Asn129Lys
BCIE, DNEPPK, IBS, MECD, 
WSN, EBS, PC-1, FNEPPK, 
PC-2, SM, EPPK, M
Smith et al. (2003)
Coil 2B 3 Arg314Gln, Arg314Trp, Glu351Lys
BCIE, DNEPPK, IBS, MECD, 
EBS, PC-1, FNEPPK, PC-2, 
EPPK, M
Smith et al. (2003)








Arg314Trp - missenseAsn129Lys - missense
Gly436Trp - missense Arg302His - missense
c.
b.a.
Figure 26 | Patients with KRT82 variants confirmed to have AA. a, Clinical photos of two
patients with a missense and nonsense (LOF) mutation in KRT82, respectively. Both show hair
loss patterns characteristic of AA. b, Immunohistochemistry (IHC) staining of CD8+ T cells in 4
patients with missense mutations in KRT82. Perifollicular CD8+ T cell infiltrate is a diagnostic
characteristic of AA. c, RNA expression profiles of the ALADIN (Alopecia Areata Disease
Severity Index) inflammatory signature confirms that three patients (green bars) with KRT82
mutations (splice and missense) have increased expression of the inflammatory signature,
characteristic of AA. Additionally these three KRT82-carrying patients (green) cluster within AA
















































Genes, NCBI Homo sapiens Annotation Release 105.20190906
Type II Keratins Chr. 12q13a.
b.
Figure 27 | AA-associated variation is specific to KRT82. a, 700 kb chromosomal locus
encompassing the type II keratin gene cluster (green bars) on chromosome 12. KRT82 is
boxed, in red. b, Table of rare damaging variants in seven other keratin genes: four type I
keratins (KRT32, KRT35, KRT39, KRT40), two type II hair keratins (KRT84, KRT85), and one
type II epithelial keratin (KRT5). None of the other keratins reach significance in any of the 3
models. Type II keratins were chosen for their similar classification and positional proximity to
KRT82. The type I hair keratins are the putative binding partners of KRT82.
Type Case Control Case Freq Ctrl Freq P-value
KRT82 19 88 2.24% 0.56% 2.03E-06
KRT84 0 13 0.00% 0.08% 1
KRT85 1 3 0.12% 0.02% 0.1906
KRT5 0 1 0.00% 0.01% 1
KRT32 0 4 0.00% 0.03% 1
KRT35 0 3 0.00% 0.02% 1
KRT39 0 16 0.00% 0.10% 1
KRT40 0 29 0.00% 0.19% 0.4014
KRT82 47 376 5.54% 2.40% 9.19E-07
KRT84 25 428 2.94% 2.74% 0.6668
KRT85 8 159 0.94% 1.02% 1
KRT5 3 80 0.35% 0.51% 0.8012
KRT32 6 111 0.71% 0.71% 1
KRT35 12 269 1.41% 1.72% 0.5869
KRT39 8 127 0.94% 0.81% 0.693
KRT40 17 267 2.00% 1.71% 0.4973
KRT82 51 404 6.01% 2.58% 2.18E-07
KRT84 25 457 2.94% 2.92% 0.9168
KRT85 25 344 2.94% 2.20% 0.999
KRT5 6 144 0.71% 0.92% 0.709
KRT32 6 142 0.71% 0.91% 0.7081
KRT35 12 284 1.41% 1.82% 0.5053
KRT39 8 127 0.94% 0.81% 0.693
KRT40 18 267 2.12% 1.71% 0.3438
LOF
LOF + missense
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Telogen TelogenAnagen Catagen
p22 p31 p43 p90
Figure 29 | KRT82 is expressed exclusively in anagen. a, IF of KRT82 (green) in postnatal (p)
mouse skin. Mouse HFs are in telogen at postnatal days 22 and 90 (p22, p90), in anagen at p31,
and catagen at p43. Cuticular staining of KRT82 is only observed in the p31 (anagen) HF. White
dashed line outlines the hair shaft cuticle. Weak staining observed in mouse epidermis may be a
result of green autofluorescent properties of skin epidermal cells. b, Western blot analysis of whole
mouse skin at varying stages of the hair cycle shows that keratin protein is only present in the
anagen phase (p31) of the mouse hair cycle.

































































Figure 30 | Functional KRT82 expression is reduced in AA HF and skin. a, IF staining of KRT82 (green) in
human healthy control and AA HF. Dashed line outlines the cuticle, dotted line represents the Line of Auber b,
RNA expression of KRT82 from whole skin scalp biopsies of control, AAP nonlesional sites, AAP lesional sites,
and AT/AU sites. Each circle represents one sample. Statistical analysis was performed using unpaired t-test
with Welch’s correction. *=p<0.05, ****p<0.0001. c, Scalp RNA expression of patients carrying KRT82 variants at
nonlesional (Variant Nonlesional) and lesional (Variant Lesional) sites compared to AA patients without KRT82
mutations (Nonlesional and Lesional) and controls without AA or KRT82 mutations. d, IHC of KRT82 and CD8 in








































































Defining the genetic architecture of autoimmune diseases is complex due to their 
polygenic nature and heterogenous tissue interactions between the immune system and the 
target organ. The common immune pathways among different autoimmune diseases explains in 
part the shared genetic susceptibility to general autoimmunity, however, the divergent 
mechanisms of tissue-specific attack (i.e. HF in AA, myelin sheath in MS, melanocytes in 
vitiligo, islet cells in type I diabetes, etc.) remain less well understood. Identifying genes that 
contribute to dysfunction in the target organ itself is crucial for fully defining the genetic 
architecture across the broad class of autoimmune diseases. Discovery of target-organ risk 
genes unique to a given disease may reveal the mechanism of action, and uncover therapeutic 
targets aimed at mitigating end organ dysfunction, rather than subjecting autoimmune disease 
patients to the substantial toxicities of broad spectrum and lifelong immunosuppression.   
The overarching goal of my thesis was to elucidate the contribution of genetic variation 
in genes specific to the target-organ in autoimmune disease and determine how disruption of 
target tissue biology contributes to autoimmune-mediated attack. In this context, AA was an 
ideal model to study due to the accessible and regenerating nature of the targeted organ, the 
HF. My thesis focused on target-organ dysfunction to elucidate the mechanisms of target 
selection that differentiates the autoimmune diseases. In AA, genetic loci shared with other 
autoimmune diseases include CTLA4, IL21/2, IL2RA, PRDX5, IKZF4, ERBB3, MICA, HLA-
DQA, most of which have demonstrated roles in immune signaling and function. These common 
pathways can help explain aberrant modifications in the immune system that result in 
inflammatory responses and autoreactive lymphocytes across autoimmunity. However, it 
remains uncertain as to why autoreactive lymphocytes react to antigens in the target organ of 
one disease but another. The answer to this question lies in the target tissue, and how 
disruption to the local biology results in improper recognition by the immune system. In order to 
understand whether genetic variation plays a role in target-tissue biology, we must focus on 
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genetic associations unique to each autoimmune disease. This will provide the groundwork for 
novel therapeutics targeting new relevant disease pathways, instead of treating with modest 
effect immunosuppressants repurposed for multiple autoimmune diseases. The significant 
advances in NGS methods over the past decade allowed us to utilize two distinct yet powerful 
sequencing approaches in order to investigate genetic variation in HF-specific genes.  
First, based on our hypothesis that GWAS associations unique to AA will play a target-
specific role, we used targeted sequencing to determine the complete genomic sequence 
(coding and non-coding) of a GWAS-associated locus. Our previous GWAS and meta-analysis 
identified at least 14 risk loci associated with AA susceptibility, only two of which, STX17 and 
ULBP3/6, were not implicated in other autoimmune diseases. To address the role of genetic 
variation in HF integrity, we selected STX17, a gene that was exclusively associated with AA 
(and not other autoimmune diseases), is highly expressed in the hair follicle, and had a known 
genetic role in hair pigmentation. The GWAS association was detected at a common variant, 
rs10760706, that resided in intron 6 of STX17. To identify the complete scope of variants in the 
region that may be driving this association, we used a hypothesis-driven targeted sequencing 
approach.  
Secondly, we used WES to investigate the role of rare variants in AA. Due to the 
unbiased nature of this technique, we were interested in identifying any genes that had rare 
variant enrichments and novel associations with AA.  To our surprise, only one gene, KRT82, a 
hair specific type II keratin, reached genome-wide significance with rare variants enriched in AA. 
Using these two methods, I investigated both common and rare variation in AA. I functionally 
defined the mechanisms by which genetic perturbances in these HF-expressed genes, SXT17 
and KRT82, contribute to disease pathogenesis. These findings elucidated the effect of 
common and rare genetic variants on the disruption of hair follicle function in AA and serve as 




Targeted Sequencing of GWAS-associated locus 
 As discussed in previous sections, one of the main limitations of GWAS is the lack of 
resolution to determine the causal disease variant(s) in a given associated region. Since GWAS 
is the main method for identifying pathogenic common variation in complex diseases, the true 
causal variant(s) and their downstream effects remain largely undiscovered in many common 
disorders. As a result, fine mapping and targeted sequencing of GWAS associated loci were 
implemented to identify causal variants within the region. In our study, we designed a custom 
sequencing chip that contained whole exome sequencing (WES), in addition to genomic 
sequencing of large regions customized to include GWAS loci. We included all 14 of our GWAS 
regions, in addition to other genes with potential implications in AA pathology. Using this 
approach, we sequenced the entire STX17 GWAS region spanning 550 kb in 849 AA patients 
and 62 controls and defined the risk haplotype driving AA disease risk. This approach enabled 
us to resolve the surrounding LD block for additional common variants contributing to disease 
and functionally annotate their effects. The success of this approach would not have been 
possible without the significant advances made in sequencing technologies in the years leading 
up to this study.  
 
Novel role for STX17 in melanocyte biology 
We performed fine mapping targeted sequencing of the 550 kb GWAS-associated 
STX17 region in 849 AA patients to understand the correlation between STX17 variation and 
hair pigmentation in the context of AA disease. We identified 35 non-coding STX17 variants that 
resided on the same risk haplotype as the initial GWAS SNP (rs107060706) associated with AA 
susceptibility. We used this sequencing data to define a ~64.6 kb haplotype that contained 35 
common non-coding variants, including the AA and human hair color GWAS SNPs (rs10760706 
and rs9556, respectively). The presence of a known hair pigmentation variant on our AA risk 
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haplotype underlined the correlation between AA and hair pigment biology.33 of these risk 
variants were significantly enriched in the AA population.  
Using the publicly available database, GTEx, we found that all 35 SNPs on the risk 
haplotype had a regulatory effect on the expression of STX17 in the skin. To understand 
whether this functional effect was relevant to AA, we used multi-dimensional genome 
sequencing and skin expression data from patients and discovered that 32 significant AA 
variants were skin eQTLs that significantly downregulated expression of STX17 in AA skin. This 
integrative approach revealed the effect of these variants in total skin tissue RNA, however, due 
to the heterogenous nature of the skin, we were unable to distinguish the precise cell type 
implicated. In order to resolve this question, we used in silico methods that annotated regulatory 
regions across the STX17 gene in the three relevant skin cell types: fibroblasts, keratinocytes, 
and melanocytes. These analyses revealed that two variants (rs7039716 and rs2416935) fell in 
the promoter region of STX17 in all skin cell types and one (rs7027813) resided in a melanocyte 
specific enhancer. These three variants are likely to be the driving functional effects of the 
STX17 risk haplotype, and moreover, indicated a preferential effect of STX17 regulation in 
melanocytes. Concordantly, immunofluorescent (IF) staining of AA hair follicles revealed 
dysregulated expression of STX17 proximal to dysmorphic follicular melanocytes.  
Due to the increased frequency of melanocyte-specific enhancers in STX17, the 
presence of one associated SNP in a melanocyte enhancer, and clinical associations of AA with 
pigmentary phenotypes, we performed in vitro analyses of STX17 function in primary human 
melanocytes. Since AA patients with risk variants have decreased expression of STX17 in the 
scalp, we used an siRNA knockdown model to recapitulate AA. Using this approach, we 
reported a novel role for STX17 in melanocyte biology that was autophagy independent. We 
found that in the absence of STX17, melanocytes were unable to produce melanin as efficiently. 
The melanocytes were still able to produce a lower volume of melanin, which was supported by 
the presence of pigmented late melanosomes. In fact, the number of late-stage, pigmented 
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melanosomes and total melanosomes were unchanged after STX17 knockdown. Since the total 
number of melanosomes was unchanged, but the melanin content was reduced, we 
hypothesized that the melanosomes were unable to produce melanin as efficiently within the 
organelles. Interestingly, the pre-pigmented early-stage melanosomes were slightly, but 
significantly reduced after STX7 depletion. The role of early stage melanosomes is to provide 
structure to the organelle via PMEL fibrils, onto which melanin can be deposited in stage III and 
IV melanosomes. We observed that STX17 co-localized with MART1 at baseline and after 
melanogenesis stimulation, suggesting that STX17 may play a role in MART1 trafficking. The 
reduction of early stage melanosomes in STX17-deficient cells supports this hypothesis, since 
cells would be unequipped to efficiently traffic the critical structural protein, MART1, to the early 
melanosomes. Moreover, lack of integral melanosome proteins would inhibit the organelle’s 
ability to efficiently undergo melanogenesis, as we observed in the STX17 knockdown 
conditions. Finally, we tested whether loss of STX17 would result in accumulation or 
degradation of melanosome cargo proteins. We found that levels of TYR, a protein that is 
present in late stage melanosomes, were not affected by STX17 reduction. However, early 
stage protein, MART1, accumulated in STX17-knockdown melanocytes.  
This finding is interesting for two main reasons. First, the function of MART1 in the 
melanogenesis pathway is not well documented; however, it has been reported to play a critical 
role in the trafficking, processing, and functioning of PMEL102. MART1 and PMEL co-localize in 
the peri-nuclear area and form a complex in the ER, the Golgi, and stage I and II 
melanosomes102. The stability and expression levels of PMEL are dependent on MART1, and in 
its absence, PMEL is unable to efficiently traffic to early melanosomes. The MART1-PMEL 
complex is relevant to our findings, since we observed MART1-STX17 colocalization and an 
accumulation of MART1 in the absence of STX17. We postulate that STX17 assists in the 
transport of the MART1 to melanosomes which subsequently regulates PMEL expression, 
processing, and trafficking to early melanosomes. Furthermore, STX17-depletion causes 
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aberrant MART1 and consequentially PMEL trafficking resulting in the decreased formation of 
early melanosomes, inefficient melanin production, and accumulation of MART1.  
Second, MART1 has well-documented antigenic properties in cancer and autoimmunity 
literature, which is extremely relevant in the context of disease. The discovery of MART1 
(Melanoma antigen recognized by T cells 1) was first identified in 1994 and aptly named 
because of its initial discovery as an antigen recognized by cytotoxic lymphocytes in melanoma 
patients163,164. It was found to be exclusively expressed in a subset of melanoma cell lines, 
melanocytes, and retinal cells164. In melanoma studies, MART1 was recognized by CD8+ T cells 
and capable of activating lymphocytes activation and inducing lysis of melanoma cells, 
indicating the cytotoxic activity 103,165-167. In another autoimmune disease targeting the skin, 
vitiligo, MART1 was proposed as an auto-antigen due to the high frequencies of melanocyte-
specific cytotoxic T lymphocytes that recognized MART1105,168,169. In the rare autoimmune 
disorder, Vogt-Koyanagi-Harada disease, MART1 was capable of inducing cytotoxic T 
lymphocytes to lyse melanocytes170. Moreover, an elegant study by Gilhar et al implicated 
MART1 as a potential autoantigen in AA131. This work showed that human MART1, in addition 
to PMEL, was sufficient to activate AA scalp T cells and induce hair loss in an explant/ SCID 
mouse model of disease. The antigenic nature of MART1 in both melanoma and autoimmune 
diseases supports its potent immunogenic nature and ability to elicit T cell responses. Taken 
together with work presented in this thesis, we showed that genetic variants in AA patients 
decrease STX17 in the scalp skin, and subsequently that reduced STX17 levels in melanocytes 
result in an accumulation of a known antigen, MART1. We propose that accumulation of MART1 
has the capability to induce cellular dysfunction or aberrant antigen presentation that can result 
in subsequent autoimmune attack of the pigmented hair follicles.  
Based on our findings, we propose the following model. Individuals carrying the AA risk 
haplotype are susceptible to disease through the downregulation of STX17 in the skin. In the 
absence of STX17, the PMEL/MART1 complex is not efficiently transported to the stage I 
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Figure 31 | Proposed model of STX17-mediated cargo trafficking. 
Under normal conditions, STX17 aids in trafficking MART1 to early 
melanosomes. STX13 has an established role TYR trafficking. In the 
absence of STX17, MART1 is not trafficked to forming melanosomes 
causing a de-pigmentation phenotype and accumulation of MART1 
antigen that is aberrantly present to auto-reactive immune cells.  
melanosomes. As a result, there is a reduction in early melanosome numbers. We postulate the 
presence of a compensatory mechanism since melanosomes still form, mature, and produce 
reduced (but not absent) melanin pigment. However, the deficiency of critical structural protein, 
PMEL, in melanosomes results in the inability to produce melanin efficiently, lowering the total 
production of melanin in the cell. Finally, in the absence of STX17, MART, a member of the 
early melanosome machinery, is mis-trafficked and accumulates in the cell, and may be 
aberrantly presented to auto-reactive CD8 + T cells through MHC1 antigen presentation (Figure 
31). Prior work supports 
the validity of MHC I 
presentation of MART1 
through the ubiquitination 
and proteasomal 
degradation pathways171. 
In our model, increased 
MART1 presentation and 
identification by 
inflammatory T cells 
would elicit attack on the 
follicular melanocytes 
and surrounding HF unit, resulting in AA-mediated immune attack. We recognize that this model 
most likely accounts for a subset of AA cases and that disease presence is dependent on a 
range of other factors, such as gene-gene interactions, the presence of auto-reactive immune 
cells, and environmental insults. Nonetheless, our findings invite a novel mechanism linking 
genetic predisposition in a HF gene and consequential disruption of the melanocyte pathway in 
AA pathogenesis.  
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Although more work will be needed to further define the precise trafficking role of STX17 
in melanogenesis, the role of SNARE proteins in melanocyte enzyme trafficking is not without 
precedent. To date, four SNARE proteins (VAMP7, STX3, STX13, and SNAP23) have well-
documented roles in cargo trafficking and membrane fusion in the melanosome maturation 
pathway172. All four SNARE proteins were demonstrated to have a role in TYRP1 transport to 
melanosomes via two separate complexes, the VAMP7-STX13 complex and the VAMP7-STX3-
SNAP23 complex (Figure 31)172-174. Additionally, VAMP7 and STX13 played a role in TYR cargo 
transport and biogenesis of PMEL+ melanosomes (Figure 31)174. Furthermore, in the absence 
of STX13, TYR is misrouted and PMEL and TYRP1 mis-localized to the lysosomes174. It is 
interesting to note that depletion of either STX3 or STX13 result in hypopigmentation172, a 
similar phenotype to what we observe in STX17-depleted cells. The dependence of 
melanosome cargo trafficking on other SNARE proteins supports a potential role for STX17 in 
protein transport and membrane fusion with maturing melanosomes. Additionally, the current 
role of SNARES is mostly in late stage protein trafficking, and understanding the machinery for 
early stage cargo trafficking, such as PMEL and MART1, remains largely unknown. The results 
presented in this thesis support a plausible role for STX17 in the transport of the PMEL/MART1 
complex to early melanosomes.  
In conclusion, we utilized targeted sequencing to resolve a GWAS associated disease 
region and annotated the functional effects of the risk variants on regulatory expression in AA. 
We reported that STX17 is necessary for melanogenesis and that reduction of STX17 resulted 
in accumulation of melanocyte antigens and increased immunogenicity of the hair follicle. We 
determined that the accumulation and mis-localization of melanosome proteins in the absence 
of STX17 supported a strong role for enzyme trafficking to early melanosome organelles. This 
work addresses a long-standing, widely observed phenomenon of preferential attack of 
pigmented HFs and provides a mechanistic link between genetic AA risk and melanocyte 




Whole Exome Sequencing of 849 AA patients 
To identify the role of rare variants in AA risk burden, we next performed whole exome 
sequencing (WES) on 849 AA patients compared to 15,640 controls using an unbiased 
genome-wide approach. This enabled us to investigate whether rare variation in coding 
sequences plays a role in AA susceptibility. WES is now a cost-effective approach (compared to 
Whole Genome Sequencing), and its success has been well-documented in identifying rare 
coding variants associated with other complex diseases such as ALS and Alzheimer’s 
Disease6,51. Based on these successes of WES in complex diseases and the potential role of 
rare variation in the ‘missing heritability’ paradigm, we selected WES as the appropriate 
approach for identifying novel rare coding mutations in AA. This strategy also implemented the 
use of gene-level burden analysis models, which aggregate genetic variants across a gene and 
compare genetic burden in cases compared to controls. Gene-collapsing analysis approaches 
were necessary to identify significant associations, since it provided aggregated power to test 
association across an entire candidate gene, whereas variant-level significance would be 
unattainable. As discussed previously, detection of individual variant association is not feasible 
in modest-sized studies because power to detect statistically significant associations decreases 
as MAF decreases due to the lack of observations of the given rare allele. Together, these 
approaches revealed a previously unknown AA candidate gene association and provided a 
major new insight into genetic mechanisms that predispose individuals to AA disease 
susceptibility.  
 
Rare variants in KRT82 contribute to disease risk 
By utilizing WES together with gene-level burden analyses, we identified a novel 
association between rare variation in KRT82 and AA disease risk. We surveyed the entire 
exome for genes that harbored an increased frequency of rare, damaging mutations in AA 
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cases compared to controls. This allowed us to identify genes with damaging mutations that 
contributed to disease risk. Furthermore, discovery of novel genetic contributions to AA provided 
insight into a novel disease mechanism and how loss of functional proteins in the HF may play a 
role in AA pathogenesis. 
In Chapter 3, I successfully identified a type II hair keratin, KRT82, which harbored a 
significantly higher frequency of rare, damaging mutations in AA patients (6.0%) compared to 
controls (2.6%) (p=2.18E-07). From our cohort of 849 AA patients, we identified 51 individuals 
who were heterozygous for one of the eleven rare damaging mutations that were predicted as 
loss of function, missense, and splicing mutations; suggesting a haploinsufficiency model of 
disease. Previous reports have identified keratin haploinsufficiency in the context of two 
diseases: 1) LOF mutations resulted in KRT5 (type II) haploinsufficiency in Dowling-Degos 
Disease175; and 2) KRT14 (type I) haploinsufficiency from LOF mutations in Naegeli-
Franceschetti-Jadassohn syndrome176. The eleven variants we identified in AA patients fell in 
highly conserved residues and the majority resided in keratin domains established as disease-
causing in other disorders. Since these mutations were all predicted to have a damaging effect 
on protein function, we interrogated the expression of KRT82 in AA and found that both scalp 
biopsies and HFs exhibited reduced levels of functional expression. We also noted that patients 
with one of the damaging KRT82 mutations, and absent KRT82 expression in the HF cuticle, 
had increased CD8+ T cell infiltrates, the hallmark characteristic histopathology of disease.  
Previous knowledge of KRT82 was limited to a type II hair keratin with specific cuticle 
layer expression in the human hair follicle. Its potential association with HF dysfunction was not 
previously well-studied. Interestingly, three previous reports implicated KRT82 expression in 
hair loss phenotypes in human and mouse studies. KRT82 is highly conserved across 
mammalian species, including mus musculus (Figure 25). First, one mouse model of cyclic 
alopecia is a result Sox21 knockout141. In response to loss of Sox21, the mice expressed altered 
levels of several keratins and keratin-associated proteins, including a striking decrease in 
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murine Krt82. Moreover, Sox21-/- knockout mice were unable to form healthy hair shaft cuticles 
and completely lost and regrew their hair in cyclic waves. Consequentially, Sox21 was proposed 
to be a regulator of keratins and keratin-associated proteins that are necessary for hair shaft 
cuticle keratinization. Due to the reported repressor function of Sox21, it is likely that the effects 
on keratin expression are mediated through another unknown transcriptional repressor that is 
the direct target of Sox21141. The loss of KRT82 and healthy cuticle structures in a mouse model 
of cyclic alopecia strongly supports an important role for KRT82 in hair follicle function. 
The other two studies indirectly integrate KRT82 expression levels with AA pathology. 
Previous work in our lab developed the ALADIN score (ALopecia Areata Disease Severity 
INdex) as a clinical and research tool for monitoring AA disease status using a distinct 
molecular signature dependent on a subset of genes differentially expressed in patients and 
controls124. It is also capable of deciphering disease severity (Control vs AAP vs ATAU)124. 
ALADIN is dependent on the expression profiles of only 18 genes divided into 3 signatures 
(Cytotoxic T Lymphocyte, Interferons, and Keratins) as markers of disease. The 8 signature 
keratin genes are decreased in patients. Interestingly, KRT82 is one of the defining genes of the 
Keratin molecular signature in ALADIN, which was developed several years prior to the 
discovery of KRT82 variants in this thesis60. Since ALADIN is a distinguishing tool in AA to 
measure disease status, progression, and drug response, the inclusion of KRT82 points to an 
integral role for its expression in disease pathology.  
Additionally, recent work published by our lab investigated the role of skin-specific 
master regulators in the context of autoimmunity177. The identification of master regulators can 
provide information about disease mechanisms, driver mutations, and druggable targets for 
therapeutic intervention. In autoimmune diseases and other heterogenous diseases, 
interactions between different implicated tissues, such as the skin and the immune infiltrate in 
AA, can convolute regulatory networks and hinder accurate identification of the driving master 
regulators. By using differential gene expression profiles and mapping to skin regulatory 
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networks, our lab effectively deciphered the molecular profiles that regulate disease 
pathogenesis and induce immune infiltrate recruitment to skin in AA. 123 genes were annotated 
as skin-specific gene signatures that were differentially expressed in AA scalp and were 
responsible for end-organ gene dysfunction in disease, including immune infiltrate recruitment. 
Interestingly, one of these signature genes that informed the master regulator analysis was 
significant decreased expression of KRT82. Of the four potential type I keratin binding partners 
of KRT82 (KRT32, KRT35, KRT39, KRT40), three including KRT32, KRT35, and KRT40 were 
also signature genes that informed the analysis. Subsequently, two master regulators, IKZF1 
and DLX4, were identified to regulate more than 60% of the AA skin gene signature. 
Furthermore, overexpression of IKZF1 and DLX4 in vitro resulted in NKG2D-dependent 
cytotoxicity in primary hair/skin cells. KRT82 specifically interacted with DLX4, a homeobox 
transcription factor. Even though the networking algorithm is unable to infer direction, we can 
assume that KRT82 is the regulatory target of DLX4 because of DLX4’s classification as a 
transcription factor and master regulator. Intriguingly, in one specific cellular setting, TGF-β 
suppressed DLX4 expression. This is relevant to disease since TGF-β is an immunosuppressive 
molecule that is responsible in part for maintaining immune privilege of the hair follicle. We 
postulate that when immune privilege collapses in AA, TGF-β levels decrease, DLX4 increases 
expression and induces regulatory changes in skin-specific gene signatures (including KRT82), 
which subsequently recruit immune infiltrate and result in NKG2D-cytotoxicity. These findings 
included both KRT82 and its potential hair shaft cuticle type I keratin binding partners as 
members of the molecular profile responsible for immune infiltration induction in AA skin. Taken 
together, these studies lend additional support for the crucial role of KRT82 in healthy hair 
follicle function and support our evidence for the absence of KRT82 in association with disease 
pathology. In summary, the work presented in Chapter 3 provides a genetic explanation to the 
reduced expression of KRT82 that has been observed in previous studies.  
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We propose four potential mechanisms for the role of KRT82 in cuticle formation and 
subsequent AA pathogenesis: 1) loss of structural integrity renders the HF vulnerable to 
infiltration; 2) inability to bind to type I keratin partners results in increased antigen availability; 3) 
loss of expression induces premature entry into catagen; and 4) increased ROS levels may 
result in a metabolically vulnerable tissue.  
First, we postulate that loss of a critical cuticle keratin, such as KRT82, would result in a 
structurally defective cuticle during anagen. The loss of functional KRT82 would prevent 
accurate cross-linking between KRT82 and its type I binding partner. With a structurally 
compromised cuticle, the hair shaft would not be ineffectively protected from mechanical and 
environmental insults. Additionally, without the outer layer of the protective cuticle the hair shaft 
could be rendered vulnerable to inflammatory auto-reactive T cells, thus inciting the AA immune 
attack. In support of this mechanism, Tobin et al. previously showed absent or defective hair 
shaft cuticles in AA exclamation mark hairs (EMH)56. Furthermore, areas of the hair shaft 
without cuticles revealed the most disorganized shaft damage. This supports a protective role of 
the cuticle in shielding the hair shaft from potential insults associated with the AA immune 
attack. Additionally, structurally defective cuticles were observed in the Sox21-/- knockout mice 
with cyclic alopecia, further supporting a critical role for cuticle structural integrity in proper hair 
shaft growth and HF maintenance141.  
Second, the absence of KRT82 from AA cuticles may result in the aggregation of its type 
I binding partners (KRT32, KRT35, KRT39, KRT40). In the absence of functional KRT82, the 
type I cuticle keratins cannot properly dimerize and keratinize to form the hair shaft cuticle. The 
type I keratins would either be unable to bind to their type II partner (KRT82) and accumulate in 
the cells; or improperly form disrupted dimers that could be targeted for degradation and 
aberrantly presented to immune cells. Interestingly, previous reports support a role for 44/46 
kDa keratins as auto-antigens in AA patients95. Since the size of type I keratins range from 40-
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48 kDa, we propose that unbound type I keratins in the hair shaft cuticle may be aberrantly 
recognized by the immune system as autoantigens in the absence of functional KRT82.  
Third, KRT82 is expressed in the hair shaft cuticle only while the hair shaft is actively 
proliferating and growing during anagen. One highly accepted pathomechanism of AA onset is 
that the AA HF enters catagen prematurely, thereby resulting in hair loss54,178. Premature 
catagen induction in AA HFs is a widely accepted mechanism of disease, and perhaps the 
absence of KRT82 (or a functional hair shaft cuticle) is responsible for this phenotype. In 
support of this, the Sox21-/- cyclic alopecia mouse model had increased hair shaft detachment in 
catagen, but not anagen, suggesting that the catagen HF is dependent on the hair shaft cuticle 
and IRS cuticle interactions to remain anchored141. We postulate that in the absence of a 
structurally intact cuticle, the HF may enter catagen prematurely, and become unable to anchor 
the hair shaft, resulting in hair loss.  
Finally, the well-established roles of intermediate filaments in preventing cell damage 
and oxidative stress response may help elucidate the mechanism of KRT82 function in anagen 
HF biology179. The role of ROS in the growing anagen hair follicle has been previously 
characterized180. Tight regulation of oxidative stress is required to carry out necessary functions 
without inducing cellular stress. In the hair follicle, an oxidative environment is required for 
keratin cross-linking180. As a result, the anagen hair follicle generates high levels of ROS above 
the Line of Auber, with highest levels at the “ring of fire” where the hair shaft outer cortex and 
cuticle form180. Interestingly, this localization coincides with the zone of KRT82 expression in the 
healthy hair follicle. However, in the AA hair follicle, KRT82 is reduced or absent, and we 
postulate that the high levels of ROS generated proximal to the growing shaft cannot be utilized 
to mediate KRT82 crosslinking with its binding partner. As a consequence, ROS levels may 
accumulate within the hair follicle, leaving it metabolically vulnerable to ROS-induced cellular 
stress. In support of this hypothesis, the skin of AA patients exhibits increased oxidative stress 
markers, such as lipid peroxidation and superoxide dismutase (SOD) levels181,182. We postulate 
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that the bulb may be rendered metabolically vulnerable due to excess ROS not utilized by 
keratin cross-linking reactions during cuticle formation. This vulnerability may result in 
unregulated cell death and/or aberrant immune infiltration of the HF, inciting AA disease.  
The work reported in Chapter 3 reports the successful identification of a disease-relevant 
gene, KRT82, which harbors rare variation in 6% of AA patients. We show that genetically 
susceptible individuals carry rare damaging mutations in KRT82 that are predicted to cause 
protein dysfunction. Concordantly, functional KRT82 levels are decreased in the skin and HF 
cuticles of AA patients. This novel finding presents a potential disease mechanism for genetic 
predisposition to disrupted hair shaft integrity and AA. Future studies may further elucidate the 




 In my thesis work, I used two sequencing approaches to understand how both common 
and rare risk variants in genes expressed in the hair follicle contribute to AA autoimmune 
susceptibility. The implication of genetic perturbations in the HF within the context of AA 
pathology has yet to be explored and using modern genetic approaches we identified novel 
biological mechanisms underlining HF dysfunction and pathogenesis. Understanding target 
organ function and how genetic variants disrupt their integrity can help us elucidate the complex 
heterogenous interactions of autoimmune disorders. Additionally, by identifying target organ 
dysfunction, we may gain insight into novel therapeutic interventions to correct such aberrant 
function(s), instead of relying solely on lifelong immunosuppression for patients. This thesis 
work distinguishes two types of variation leading to HF susceptibility: a common risk haplotype 
in STX17 that exerts negative regulatory effects on follicular melanocytes in about 36% of 
patients, and rare mutations in KRT82 that disrupt cuticle integrity in approximately 6% of AA 
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cases. These findings open up the possibility of genetically informed precision medicine 
approaches for the treatment of AA in the future.  
 Understanding the genetic architecture of rare and common diseases alike is crucial for 
the progress of the scientific and biomedical fields. Interpreting how genetic variants predispose 
individuals to disease can inform our efforts in tailoring treatments to patients in an efficient, 
effective, and genetically determined manner. The past decade has seen unparalleled advances 
in sequencing technologies that have amassed large amounts of data and contributed 
substantially to our knowledge of the human genome. Databases such as ExAC and gnomAD 
were created to collect sequencing data across thousands of individuals and ethnicities and 
provide public access to this data for the entire scientific community. Yet, with the accumulation 
of extensive amounts of genetic information, challenges arose in the accurate interpretation of 
variants. In response, PolyPhen was designed to predict the effect of coding variants, while the 
ENCODE project collated DNA regulatory annotations spanning the genome in order to interpret 
non-coding variants. Through these types of consortia, researchers were not only able to 
identify variants associated with disease risk but were also able to predict whether these 
variants would have damaging effects on protein products or gene regulation, effectively 
informing the likelihood of pathogenicity. Due to the high variability between individual human 
genomes, these efforts have been crucially important in identifying meaningful variants with 
actual effects on disease across patient cohorts. Without these advances in the field, the work 
presented herein would have been infinitely more challenging, if not impossible. As the field 
continues to move forward at a rapid pace, our understanding of the genome, disease, and the 
human condition will simultaneously and swiftly evolve. I am grateful to have contributed this 
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